('<?xml version="1.0" ?>\n'
 '<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January '
 '2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">\n'
 '<PubmedArticleSet>\n'
 '<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID '
 'Version="1">41491968</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>06</Day></DateRevised><Article '
 'PubModel="Print-Electronic"><Journal><ISSN '
 'IssnType="Electronic">2047-783X</ISSN><JournalIssue '
 'CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>European '
 'journal of medical research</Title><ISOAbbreviation>Eur J Med '
 'Res</ISOAbbreviation></Journal><ArticleTitle>Downregulation of USP39 in '
 'sepsis reflects immune dysfunction and offers diagnostic and prognostic '
 'value.</ArticleTitle><ELocationID EIdType="doi" '
 'ValidYN="Y">10.1186/s40001-025-03709-7</ELocationID><Abstract><AbstractText '
 'Label="BACKGROUND" NlmCategory="BACKGROUND">USP39 is involved in mRNA '
 'splicing and stress responses. This study analyzed USP39 expression and its '
 'clinical relevance in sepsis, aiming to provide a novel treatment target for '
 'sepsis.</AbstractText><AbstractText Label="METHODS" '
 'NlmCategory="METHODS">The RNA-seq datasets were used for analyzing the '
 'expression profile and clinical significance of USP39 in both sepsis and '
 'control groups. Functional pathway enrichment was performed using GSEA and '
 'GSVA with the clusterProfiler package (3.14.3). Immune infiltration was '
 'evaluated via single-sample GSEA (ssGSEA). The prognostic value of USP39 was '
 'assessed utilizing Cox regression, and its diagnostic performance was '
 'determined via receiver operating characteristic (ROC) curve analysis '
 'employing the survival (3.5.7) and pROC (1.18.5) packages, respectively. For '
 'single-cell RNA-seq (scRNA-seq) data (GSE175453), we performed quality '
 'control, normalization, principal component analysis (PCA), batch '
 'correction, clustering, and Uniform Manifold Approximation and Projection '
 '(UMAP) visualization employing the Seurat 4.4.0 package. THP-1 cells were '
 'treated with lipopolysaccharide (LPS) to mimic septic injury. USP39 was '
 'overexpressed via pcDNA3.1 transfection. Cellular assays were conducted to '
 'measure cell viability, apoptosis, and inflammatory cytokines (IL-1&#x3b2;, '
 'IL-6, TNF-&#x3b1;).</AbstractText><AbstractText Label="RESULTS" '
 'NlmCategory="RESULTS">Our study found that USP39 was significantly '
 'downregulated in sepsis patients and was associated with age, diabetes, and '
 'Intensive Care Unit (ICU)-acquired infections. Functional enrichment '
 'analysis revealed that high USP39 expression was linked to metabolic '
 'processes, primary immunodeficiency, and spliceosome, and immune response '
 'and inflammation pathway. In addition, USP39 also exhibited a high '
 'diagnostic value and was identified as an independent prognostic marker in '
 'sepsis. ssGSEA revealed higher infiltration of CD8<sup>+</sup> T cells, '
 'activated B cells, and CD4<sup>+</sup> T cells in the high USP39 expression '
 'group, while Th17 and NK cells were more abundant in the low USP39 '
 'expression group. According to the results of scRNA-seq analysis, USP39 '
 'exhibited significant differential expressions in monocytes and T cells, '
 'with low expression observed in sepsis. Furthermore, in vitro experiments '
 'confirmed that overexpression of USP39 significantly enhanced cell viability '
 'and suppressed apoptosis in LPS-induced THP-1 cells while also inhibiting '
 'the expression of inflammatory cytokines.</AbstractText><AbstractText '
 'Label="CONCLUSION" NlmCategory="CONCLUSIONS">The significant downregulation '
 'of USP39 was correlated with both clinical features and immune infiltration '
 'in sepsis, highlighting its role in immune regulation and its potential as a '
 'prognostic biomarker.</AbstractText><CopyrightInformation>&#xa9; 2025. The '
 'Author(s).</CopyrightInformation></Abstract><AuthorList '
 'CompleteYN="Y"><Author '
 'ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhimin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department '
 'of Emergency Medicine, The Affiliated Hospital of Putian University, Putian, '
 '351100, China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiancheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department '
 'of Emergency Medicine, The Affiliated Hospital of Putian University, Putian, '
 '351100, China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Wu</LastName><ForeName>Huifeng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gastrointestinal '
 'Endoscopy Center, The Affiliated Hospital of Putian University, Putian, '
 '351100, China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, China. '
 'xmlee151@ptu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key '
 'Laboratory of Translational Tumor Medicine in Fujian Province, Putian '
 'University, Putian, 351100, China. '
 'xmlee151@ptu.edu.cn.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Song</LastName><ForeName>Conghua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gastrointestinal '
 'Endoscopy Center, The Affiliated Hospital of Putian University, Putian, '
 '351100, China. '
 'kesongs@ptu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key '
 'Laboratory of Translational Tumor Medicine in Fujian Province, Putian '
 'University, Putian, 351100, China. '
 'kesongs@ptu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList '
 'CompleteYN="Y"><Grant><GrantID>82200676</GrantID><Agency>the National '
 'Natural Science Foundation of '
 'China</Agency><Country/></Grant><Grant><GrantID>2023SZ3001PTXY01</GrantID><Agency>the '
 'Science and Technology Planning Project of Putian '
 'City</Agency><Country/></Grant><Grant><GrantID>2022KF005</GrantID><Agency>the '
 'Open Project of the Putian University Key Laboratory of Translational Tumor '
 'Medicine in Fujian '
 'Province</Agency><Country/></Grant><Grant><GrantID>X202411498008</GrantID><Agency>College '
 'Student Innovation and Entrepreneurship Training Program of Putian '
 'University</Agency><Country/></Grant><Grant><GrantID>2024106</GrantID><Agency>the '
 'Collaborative Project Between the Hospital and College of Putian '
 'University</Agency><Country/></Grant><Grant><GrantID>2024SJYL079</GrantID><Agency>the '
 'Joint Fund Project for Scientific and Technological Innovation in the Field '
 'of Medical and Health Care in '
 'Putian</Agency><Country/></Grant><Grant><GrantID>2024GGA089</GrantID><Agency>the '
 'Fujian Provincial Health Technology '
 'Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType '
 'UI="D016428">Journal '
 'Article</PublicationType></PublicationTypeList><ArticleDate '
 'DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur '
 'J Med '
 'Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList '
 'Owner="NOTNLM"><Keyword MajorTopicYN="N">USP39</Keyword><Keyword '
 'MajorTopicYN="N">Immune infiltration</Keyword><Keyword '
 'MajorTopicYN="N">Pathway activation</Keyword><Keyword '
 'MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Single-cell '
 'landscape</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval '
 'and consent to participate: Ethical approval was not required for this study '
 'because it is not involved in any human experiments. Consent for '
 'publication: Not applicable. Competing interests: The authors declare no '
 'competing '
 'interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate '
 'PubStatus="received"><Year>2025</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>6</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>6</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>6</Day><Hour>11</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId '
 'IdType="pubmed">41491968</ArticleId><ArticleId '
 'IdType="doi">10.1186/s40001-025-03709-7</ArticleId><ArticleId '
 'IdType="pii">10.1186/s40001-025-03709-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kullberg '
 'RFJ, Haak BW, Chanderraj R, Prescott HC, Dickson RP, Wiersinga WJ. Empirical '
 'antibiotic therapy for sepsis: save the anaerobic microbiota. Lancet Respir '
 'Med. '
 '2025;13(1):92&#x2013;100.</Citation></Reference><Reference><Citation>Han YC, '
 'Shen ZJ, Xiang RL, Lu B, Qian H, Li JY, et al. Long noncoding RNA and mRNA '
 'expression profiles in rats with LPS-induced myocardial dysfunction. Curr '
 'Genomics. '
 '2023;23(6):412&#x2013;23.</Citation></Reference><Reference><Citation>Parolini '
 'C. Sepsis and high-density lipoproteins: pathophysiology and potential new '
 'therapeutic targets. Biochim Biophys Acta. '
 '2025;1871(5):167761.</Citation></Reference><Reference><Citation>Cajander S, '
 'Kox M, Scicluna BP, Weigand MA, Mora RA, Floh&#xe9; SB, et al. Profiling the '
 'dysregulated immune response in sepsis: overcoming challenges to achieve the '
 'goal of precision medicine. Lancet Respir Med. '
 '2024;12(4):305&#x2013;22.</Citation></Reference><Reference><Citation>Marshall '
 'T, Dysert K, Young M, DuMont T. Pathophysiology of sepsis. Crit Care Nurs Q. '
 '2025;48(2):88&#x2013;92.</Citation></Reference><Reference><Citation>Liu D, '
 'Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced '
 'immunosuppression: mechanisms, diagnosis and current treatment options. Mil '
 'Med Res. 2022;9(1):56.</Citation></Reference><Reference><Citation>Van Damme '
 'J, Opdenakker G, Van Damme S, Struyf S. Antibodies as tools in cytokine '
 'discovery and usage for diagnosis and therapy of inflammatory diseases. Eur '
 'Cytokine Netw. '
 '2023;34(1):1&#x2013;9.</Citation></Reference><Reference><Citation>Deinhardt-Emmer '
 'S, Chousterman BG, Schefold JC, Floh&#xe9; SB, Skirecki T, Kox M, et al. '
 'Sepsis in patients who are immunocompromised: diagnostic challenges and '
 'future therapies. Lancet Respir Med. '
 '2025;13(7):623&#x2013;37.</Citation></Reference><Reference><Citation>Cao M, '
 'Wang G, Xie J. Immune dysregulation in sepsis: experiences, lessons and '
 'perspectives. Cell Death Discov. '
 '2023;9(1):465.</Citation></Reference><Reference><Citation>Xie J, Wang H, '
 'Kang Y, Zhou L, Liu Z, Qin B, et al. The epidemiology of sepsis in Chinese '
 'ICUs: a national cross-sectional survey. Crit Care Med. '
 '2020;48(3):e209&#x2013;18.</Citation></Reference><Reference><Citation>Giamarellos-Bourboulis '
 'EJ, Zinkernagel AS, De Robertis E, Azoulay &#xc9;, De Luca D. Sepsis, a call '
 'for inclusion in the work plan of the European Center for Disease Prevention '
 'and Control. Intensive Care Med. '
 '2023;49(9):1138&#x2013;42.</Citation></Reference><Reference><Citation>Van '
 'Wyngene L, Vandewalle J, Libert C. Reprogramming of basic metabolic pathways '
 'in microbial sepsis: therapeutic targets at last? EMBO Mol Med. 2018. '
 'https://doi.org/10.15252/emmm.201708712.</Citation></Reference><Reference><Citation>Marshall '
 'JC. Why have clinical trials in sepsis failed? Trends Mol Med. '
 '2014;20(4):195&#x2013;203.</Citation></Reference><Reference><Citation>Dai X, '
 'Lu L, Deng S, Meng J, Wan C, Huang J, et al. USP7 targeting modulates '
 'anti-tumor immune response by reprogramming tumor-associated macrophages in '
 'lung cancer. Theranostics. '
 '2020;10(20):9332&#x2013;47.</Citation></Reference><Reference><Citation>Gao '
 'H, Yin J, Ji C, Yu X, Xue J, Guan X, et al. Targeting ubiquitin specific '
 'proteases (USPs) in cancer immunotherapy: from basic research to preclinical '
 'application. J Exp Clin Cancer Res CR. '
 '2023;42(1):225.</Citation></Reference><Reference><Citation>Cruz L, Soares P, '
 'Correia M. Ubiquitin-specific proteases: players in cancer cellular '
 'processes. Pharmaceuticals. 2021. '
 'https://doi.org/10.3390/ph14090848.</Citation></Reference><Reference><Citation>Quan '
 'J, Zhao X, Xiao Y, Wu H, Di Q, Wu Z, et al. USP39 regulates '
 'NF-&#x3ba;B-mediated inflammatory responses through deubiquitinating '
 'K48-linked I&#x3ba;B&#x3b1;. J Immunol. '
 '2023;210(5):640&#x2013;52.</Citation></Reference><Reference><Citation>Peng '
 'Y, Guo J, Sun T, Fu Y, Zheng H, Dong C, et al. USP39 serves as a '
 'deubiquitinase to stabilize STAT1 and sustains type I IFN-induced antiviral '
 'immunity. J Invest Med. '
 '2020;205(11):3167&#x2013;78.</Citation></Reference><Reference><Citation>Xiao '
 'Z, Wei X, Li P, Chen R, Yu Z, Liang Y, et al. Impact of N-acetyltransferase '
 '10 on macrophage activation and inflammation-induced cardiac dysfunction. '
 'Cell Death Dis. '
 '2025;16(1):471.</Citation></Reference><Reference><Citation>Charoentong P, '
 'Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer '
 'immunogenomic analyses reveal genotype-immunophenotype relationships and '
 'predictors of response to checkpoint blockade. Cell Rep. '
 '2017;18(1):248&#x2013;62.</Citation></Reference><Reference><Citation>Zulibiya '
 'A, Wen J, Yu H, Chen X, Xu L, Ma X, et al. Single-cell RNA sequencing '
 'reveals potential for endothelial-to-mesenchymal transition in tetralogy of '
 'Fallot. Congenit Heart Dis. '
 '2023;18(6):611&#x2013;25.</Citation></Reference><Reference><Citation>Tian S, '
 'Chen M, Jing W, Meng Q, Wu J. miR-1204 positioning in 8q24.21 involved in '
 'the tumorigenesis of colorectal cancer by targeting MASPIN. Protein Pept '
 'Lett. '
 '2024;31(7):544&#x2013;58.</Citation></Reference><Reference><Citation>Gu Y, '
 'Jia H, Lin X, Wang L. Serum LINC01278 serves as a negative biomarker for '
 'sepsis and its up-regulation inhibits LPS-induced inflammatory response in '
 'THP-1 cells. Immunobiology. '
 '2025;230(4):153098.</Citation></Reference><Reference><Citation>Zhang L, Yang '
 'H, Liu J, Wang K, Cai X, Xiao W, et al. Metabolomics-based approach to '
 'analyze the therapeutic targets and metabolites of a synovitis ointment for '
 'knee osteoarthritis. Curr Pharm Anal. '
 '2023;19(3):222&#x2013;34.</Citation></Reference><Reference><Citation>Qiu J, '
 'Zhou T, Wang D, Hong W, Qian D, Meng X, et al. Pan-cancer analysis '
 'identifies AIMP2 as a potential biomarker for breast cancer. Curr Genom. '
 '2023;24(5):307&#x2013;29.</Citation></Reference><Reference><Citation>Liu C, '
 'Shi J, Lin B, Zhou M, Shan D, Nie J, et al. SHR6390 combined with '
 'cabozantinib inhibits tumor progression in the hepatocellular carcinoma '
 'mouse model. Curr Gene Ther. '
 '2024;24(5):453&#x2013;64.</Citation></Reference><Reference><Citation>Ning Y, '
 'Zhou X, Wang G, Zhang L, Wang J. Exosome miR-30a-5p regulates glomerular '
 'endothelial cells&#x2019; endMT and angiogenesis by modulating Notch1/VEGF '
 'signaling pathway. Curr Gene Ther. '
 '2024;24(2):159&#x2013;77.</Citation></Reference><Reference><Citation>Chen D, '
 'Xu L, Xing H, Shen W, Song Z, Li H, et al. Sangerbox 2: enhanced '
 'functionalities and update for a comprehensive clinical bioinformatics data '
 'analysis platform. iMeta. '
 '2024;3(5):e238.</Citation></Reference><Reference><Citation>Uma H, Aminu A, '
 'Cherukupalli R, Akintomide F-A, Habu A, Lawal A-A, et al. Case report: '
 'Laubry-Pezzi syndrome: confronting the lethal nexus of life-threatening '
 'complications in resource constrained settings. Congenit Heart Dis. '
 '2024;19(6):635&#x2013;45.</Citation></Reference><Reference><Citation>Wang N, '
 'Lu Y, Zheng J, Liu X. Of mice and men: laboratory murine models for '
 'recapitulating the immunosuppression of human sepsis. Front Immunol. '
 '2022;13:956448.</Citation></Reference><Reference><Citation>Stanski NL, Wong '
 'HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. '
 '2020;16(1):20&#x2013;31.</Citation></Reference><Reference><Citation>Alsayed '
 'BA, Mir R, Mir MM, Alnour TMS, Fawzy S, Ahmed MM, et al. Molecular '
 'determination of tumor necrosis factor-alpha, interleukin-8, interleukin-10, '
 'and C-X-C chemokine receptor-2 genetic variations and their association with '
 'disease susceptibility and mortality in COVID-19 patients. Curr Genomics. '
 '2024;25(1):12&#x2013;25.</Citation></Reference><Reference><Citation>Zhang Y, '
 'Ma CA, Lawrence MG, Break TJ, O&#x2019;Connell MP, Lyons JJ, et al. PD-L1 '
 'up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 '
 'gain-of-function patients. J Exp Med. '
 '2017;214(9):2523&#x2013;33.</Citation></Reference><Reference><Citation>Martin '
 'MD, Badovinac VP, Griffith TS. CD4 T cell responses and the sepsis-induced '
 'immunoparalysis state. Front Immunol. '
 '2020;11:1364.</Citation></Reference><Reference><Citation>Ryan N, Anderson K, '
 'Volpedo G, Hamza O, Varikuti S, Satoskar AR, et al. STAT1 inhibits T-cell '
 'exhaustion and myeloid derived suppressor cell accumulation to promote '
 'antitumor immune responses in head and neck squamous cell carcinoma. Int J '
 'Cancer. '
 '2020;146(6):1717&#x2013;29.</Citation></Reference><Reference><Citation>Ding '
 'R, Yu X, Hu Z, Dong Y, Huang H, Zhang Y, et al. Lactate modulates RNA '
 'splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T '
 'cells. Immunity. '
 '2024;57(3):528-540.e6.</Citation></Reference><Reference><Citation>Mattingly '
 'JR, Wu A, York AG. Regulation of adaptive immunity by lipid '
 'post-translational modifications. Immune Netw. '
 '2025;25(1):e11.</Citation></Reference><Reference><Citation>Wang Y, Zhang H, '
 'Miao C. Unraveling immunosenescence in sepsis: from cellular mechanisms to '
 'therapeutics. Cell Death Dis. '
 '2025;16(1):393.</Citation></Reference><Reference><Citation>Yuan J, Xu B, Su '
 'Y, Zhang P, Zhang X, Gong P. Identification of USP39 as a prognostic and '
 'predictive biomarker for determining the response to immunotherapy in '
 'pancreatic cancer. BMC Cancer. '
 '2025;25(1):758.</Citation></Reference><Reference><Citation>Condotta SA, '
 'Cabrera-Perez J, Badovinac VP, Griffith TS. T-cell-mediated immunity and the '
 'role of TRAIL in sepsis-induced immunosuppression. Crit Rev Immunol. '
 '2013;33(1):23&#x2013;40.</Citation></Reference><Reference><Citation>Gupta '
 'DL, Sharma A, Soni KD, Kazim SN, Bhoi S, Rao DN. Changes in the behaviour of '
 'monocyte subsets in acute post-traumatic sepsis patients. Mol Immunol. '
 '2021;136:65&#x2013;72.</Citation></Reference><Reference><Citation>Derigs M, '
 'Heers H, Lingelbach S, Hofmann R, H&#xe4;nze J. Soluble PD-L1 in blood '
 'correlates positively with neutrophil and negatively with lymphocyte mRNA '
 'markers and implies adverse sepsis outcome. Immunol Res. '
 '2022;70(5):698&#x2013;707.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation '
 'Status="Publisher" Owner="NLM"><PMID '
 'Version="1">41423877</PMID><DateRevised><Year>2025</Year><Month>12</Month><Day>22</Day></DateRevised><Article '
 'PubModel="Print-Electronic"><Journal><ISSN '
 'IssnType="Electronic">1521-3773</ISSN><JournalIssue '
 'CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Angewandte '
 'Chemie (International ed. in English)</Title><ISOAbbreviation>Angew Chem Int '
 'Ed Engl</ISOAbbreviation></Journal><ArticleTitle>Targeting the Spliceosomal '
 'Protein USP39 Through Allosteric Ligands and PROTAC-Induced '
 'Degradation.</ArticleTitle><Pagination><StartPage>e16809</StartPage><MedlinePgn>e16809</MedlinePgn></Pagination><ELocationID '
 'EIdType="doi" '
 'ValidYN="Y">10.1002/anie.202516809</ELocationID><Abstract><AbstractText>The '
 'precise regulation of gene expression is fundamental to cellular homeostasis '
 'and diversity. Dysregulation of splicing has been implicated in a range of '
 'diseases, including cancer and neurodegeneration. Ubiquitin-specific '
 'protease 39 (USP39), an essential spliceosome component lacking enzymatic '
 'activity, has remained an elusive target for pharmacological intervention. '
 'Here, we report the discovery of small-molecule ligands that selectively '
 'engage with USP39 through a thiazole scaffold, primarily interacting with '
 'its zinc finger domain. Guided by AlphaFold-based structure-activity '
 'relationship studies, we designed and optimized proteolysis-targeting '
 'chimeras (PROTACs), culminating in the development of USP39_PROTAC_V1, which '
 'harnesses the von Hippel-Lindau (VHL) E3 ubiquitin ligase for targeted '
 'degradation. Biophysical and biochemical assays demonstrated potent ternary '
 'complex formation and nanomolar-range binding affinities. In cellular '
 'models, USP39_PROTACs achieved efficient degradation of USP39 at '
 'concentrations as low as 1&#xa0;nM, with minimal off-target effects as '
 'confirmed by proteome-wide profiling. Mechanistic studies revealed that '
 'degradation was dependent on VHL recruitment and was abrogated by proteasome '
 'or neddylation inhibition. Notably, USP39 depletion recapitulated '
 "5'-splice-site-specific splicing patterns previously described, thereby "
 'validating both the mechanism of action and the therapeutic relevance of '
 'this approach-particularly for modulating splicing-associated disease '
 'pathways such as cancer and retinitis '
 'pigmentosa.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). '
 'Angewandte Chemie International Edition published by Wiley&#x2010;VCH '
 'GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author '
 'ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier '
 'Source="ORCID">0009-0009-1685-5728</Identifier><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University Frankfurt am '
 'Main, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frankfurt '
 'Cancer Institute, Paul-Ehrlich-Str. 42-44, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Prieto-Garcia</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute '
 'of Biochemistry II Frankfurt, University Hospital Building 75, Faculty of '
 'Medicine Frankfurt am Main, Theodor-Stern-Kai 7, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University Frankfurt am '
 'Main, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Heinz</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department '
 'of Theoretical Biophysics, Max Planck Institute of Biophysics, '
 'Max-von-Laue-Str. 3, 60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Matkovic</LastName><ForeName>Vigor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'of Biochemistry II Frankfurt, University Hospital Building 75, Faculty of '
 'Medicine Frankfurt am Main, Theodor-Stern-Kai 7, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Kielkowski</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department '
 'of Chemistry, Ludwig Maximilian University M&#xfc;nchen, W&#xfc;rmtalstrasse '
 '201, 81375, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Hasselbeck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University Frankfurt am '
 'Main, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Shah</LastName><ForeName>Varun '
 'Jayeshkumar</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Institute '
 'of Biochemistry II Frankfurt, University Hospital Building 75, Faculty of '
 'Medicine Frankfurt am Main, Theodor-Stern-Kai 7, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Knapp</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University Frankfurt am '
 'Main, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frankfurt '
 'Cancer Institute, Paul-Ehrlich-Str. 42-44, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Hummer</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department '
 'of Theoretical Biophysics, Max Planck Institute of Biophysics, '
 'Max-von-Laue-Str. 3, 60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'of Biophysics, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 1, '
 'D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Dikic</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'of Biochemistry II Frankfurt, University Hospital Building 75, Faculty of '
 'Medicine Frankfurt am Main, Theodor-Stern-Kai 7, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xinlai</ForeName><Initials>X</Initials><Identifier '
 'Source="ORCID">0000-0001-6441-3742</Identifier><AffiliationInfo><Affiliation>Buchmann '
 'Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University '
 'Frankfurt am Main, Max-von-Laue-Str. 15, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute '
 'for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University Frankfurt am '
 'Main, Max-von-Laue-Str. 9, D-60438, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frankfurt '
 'Cancer Institute, Paul-Ehrlich-Str. 42-44, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mildred-Scheel-Nachwuchszentrum '
 '(MSNZ), University Cancer Center (UCT) Frankfurt, University Hospital '
 'Frankfurt am Main, Theodor-Stern-Kai 7, D-60596, Frankfurt am Main, '
 'Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList '
 'CompleteYN="Y"><Grant><GrantID>CH 1690/8-1</GrantID><Agency>Deutsche '
 'Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>CH '
 '1690/5-1</GrantID><Agency>Deutsche '
 'Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>CH '
 '1690/4-1</GrantID><Agency>Deutsche '
 'Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>03ZU1109EA</GrantID><Agency>BMBF-PROXIDRUGS</Agency><Country/></Grant><Grant><GrantID>III '
 'L 5-519 / 03 / 03.001 - (0015)</GrantID><Agency>Mildred Scheel Career Center '
 'Frankfurt (Deutsche Krebshilfe); LOEWE Center Frankfurt Cancer Institute '
 '(FCI); Hessen State Ministry of Higher Education, Research and the '
 'Arts</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType '
 'UI="D016428">Journal '
 'Article</PublicationType></PublicationTypeList><ArticleDate '
 'DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Angew '
 'Chem Int Ed '
 'Engl</MedlineTA><NlmUniqueID>0370543</NlmUniqueID><ISSNLinking>1433-7851</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList '
 'Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological chemistry and chemical '
 'biology</Keyword><Keyword MajorTopicYN="N">Drug discovery</Keyword><Keyword '
 'MajorTopicYN="N">PROTAC</Keyword><Keyword '
 'MajorTopicYN="N">Spliceosome</Keyword><Keyword '
 'MajorTopicYN="N">USP39</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate '
 'PubStatus="revised"><Year>2025</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="received"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>22</Day><Hour>0</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId '
 'IdType="pubmed">41423877</ArticleId><ArticleId '
 'IdType="doi">10.1002/anie.202516809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>F. '
 'E. Baralle, J. Giudice, Nat. Rev. Mol. Cell Biol. 2017, 18, 437&#x2013;451, '
 'https://doi.org/10.1038/nrm.2017.27.</Citation></Reference><Reference><Citation>R. '
 'A. Gama&#x2010;Brambila, J. Chen, J. Zhou, G. Tascher, C. M&#xfc;nch, X. '
 'Cheng, Cell Chem. Biol. 2021, 28, 1616&#x2013;1627.e8, '
 'https://doi.org/10.1016/j.chembiol.2021.04.018.</Citation></Reference><Reference><Citation>S. '
 'Li, M. Yang, H. Shen, L. Ding, X. Lyu, K. Lin, J. Ong, P. Du, Cell 2024, '
 '187, 3284&#x2013;3302.e23, '
 'https://doi.org/10.1016/j.cell.2024.05.010.</Citation></Reference><Reference><Citation>H. '
 'Dvinge, E. Kim, O. Abdel&#x2010;Wahab, R. K. Bradley, Nat. Rev. Cancer 2016, '
 '16, 413&#x2013;430, '
 'https://doi.org/10.1038/nrc.2016.51.</Citation></Reference><Reference><Citation>J. '
 'Li, J. Zhong, J. Ye, Y. Xiang, X. Wang, Front. Oncol. 2025, 15, 1556011, '
 'https://doi.org/10.3389/fonc.2025.1556011.</Citation></Reference><Reference><Citation>R. '
 'Bai, M. Yuan, P. Zhang, T. Luo, Y. Shi, R. Wan, Science 2024, 383, '
 '1245&#x2013;1252, '
 'https://doi.org/10.1126/science.adn7272.</Citation></Reference><Reference><Citation>D. '
 'E. Agafonov, B. Kastner, O. Dybkov, R. V. Hofele, W.&#x2010;T. Liu, H. '
 'Urlaub, R. L&#xfc;hrmann, H. Stark, Science 2016, 351, 1416&#x2013;1420, '
 'https://doi.org/10.1126/science.aad2085.</Citation></Reference><Reference><Citation>C. '
 'Prieto&#x2010;Garcia, V. Matkovic, T. Mosler, C. Li, J. Liang, J. A. Oo, F. '
 'Haidle, I. Ma&#x10d;inkovi&#x107;, A. Cabrera&#x2010;Orefice, R. Berkane, G. '
 'Giuliani, F. Xu, A.&#x2010;C. Jacomin, I. Tomaskovic, M. Basoglu, M. E. '
 'Hoffmann, R. Rathore, R. Cetin, D. Boutguetait, S. Bozkurt, M. C. '
 'Hern&#xe1;ndez Ca&#xf1;&#xe1;s, M. Keller, J. Busam, V. J. Shah, I. Wittig, '
 'M. Kaulich, P. Beli, W. P. Galej, I. Ebersberger, L. Wang, et&#xa0;al. '
 'Science 2024, 386, 768&#x2013;776, '
 'https://doi.org/10.1126/science.adi5295.</Citation></Reference><Reference><Citation>Y. '
 'Zhou, F. Wang, S. Feng, M. Li, M. Zhu, Discover Oncol. 2025, 16, 749, '
 'https://doi.org/10.1007/s12672&#x2010;025&#x2010;02573&#x2010;5.</Citation></Reference><Reference><Citation>S. '
 'Wei, J. Zhang, R. Zhao, R. Shi, L. An, Z. Yu, Q. Zhang, J. Zhang, Y. Yao, H. '
 'Li, H. Wang, Cell Death Discovery 2024, 10, 121, '
 'https://doi.org/10.1038/s41420&#x2010;024&#x2010;01898&#x2010;4.</Citation></Reference><Reference><Citation>T. '
 'Y. T. Hsu, L. M. Simon, N. J. Neill, R. Marcotte, A. Sayad, C. S. Bland, G. '
 'V. Echeverria, T. Sun, S. J. Kurley, S. Tyagi, K. L. Karlin, R. '
 'Dominguez&#x2010;Vida&#xf1;a, J. D. Hartman, A. Renwick, K. Scorsone, R. J. '
 'Bernardi, S. O. Skinner, A. Jain, M. Orellana, C. Lagisetti, I. Golding, S. '
 'Y. Jung, J. R. Neilson, X. H. F. Zhang, T. A. Cooper, T. R. Webb, B. G. '
 'Neel, C. A. Shaw, T. F. Westbrook, Nature 2015, 525, 384&#x2013;388, '
 'https://doi.org/10.1038/nature14985.</Citation></Reference><Reference><Citation>R. '
 'J. Van Leuken, M. P. Luna&#x2010;Vargas, T. K. Sixma, R. M. Wolthuis, R. H. '
 'Medema, Cell Cycle 2008, 7, 2710&#x2013;2719, '
 'https://doi.org/10.4161/cc.7.17.6553.</Citation></Reference><Reference><Citation>Z. '
 'Zhang, V. Kumar, O. Dybkov, C. L. Will, J. Zhong, S. E. Ludwig, H. Urlaub, '
 'B. Kastner, H. Stark, R. L&#xfc;hrmann, Nature 2024, 630, 1012&#x2013;1019, '
 'https://doi.org/10.1038/s41586&#x2010;024&#x2010;07458&#x2010;1.</Citation></Reference><Reference><Citation>R. '
 'A. Gama&#x2010;Brambila, J. Chen, Y. Dabiri, G. Tascher, V. N&#x11b;mec, C. '
 'M&#xfc;nch, G. Song, S. Knapp, X. Cheng, JACS Au 2021, 1, 777&#x2013;785, '
 'https://doi.org/10.1021/jacsau.1c00007.</Citation></Reference><Reference><Citation>J. '
 'Wang, M. Heinz, K. Han, V. J. Shah, S. Hasselbeck, M. P. Schwalm, R. '
 'Rathore, G. Hummer, J. Zhou, I. Dikic, Cell Rep. Phys. Sci. 2024, 5, 101960, '
 'https://doi.org/10.1016/j.xcrp.2024.101960.</Citation></Reference><Reference><Citation>D. '
 'Schaefer, X. Cheng, Pharmaceuticals 2023, 16, 663, '
 'https://doi.org/10.3390/ph16050663.</Citation></Reference><Reference><Citation>M. '
 'B&#xe9;k&#xe9;s, D. R. Langley, C. M. Crews, Nat. Rev. Drug Discovery 2022, '
 '21, 181&#x2013;200, '
 'https://doi.org/10.1038/s41573-021-00371-6.</Citation></Reference><Reference><Citation>M. '
 'S. Gadd, A. Testa, X. Lucas, K.&#x2010;H. Chan, W. Chen, D. J. Lamont, M. '
 'Zengerle, A. Ciulli, Nat. Chem. Biol. 2017, 13, 514&#x2013;521, '
 'https://doi.org/10.1038/nchembio.2329.</Citation></Reference><Reference><Citation>E. '
 'S. Fischer, K. B&#xf6;hm, J. R. Lydeard, H. Yang, M. B. Stadler, S. '
 'Cavadini, J. Nagel, F. Serluca, V. Acker, G. M. Lingaraju, R. B. Tichkule, '
 'M. Schebesta, W. C. Forrester, M. Schirle, U. Hassiepen, J. Ottl, M. Hild, '
 'R. E. J. Beckwith, J. W. Harper, J. L. Jenkins, N. H. Thom&#xe4;, Nature '
 '2014, 512, 49&#x2013;53, '
 'https://doi.org/10.1038/nature13527.</Citation></Reference><Reference><Citation>J. '
 'M. Kolos, A. M. Voll, M. Bauder, F. Hausch, Front. Pharmacol. 2018, 9, 1425, '
 'https://doi.org/10.3389/fphar.2018.01425.</Citation></Reference><Reference><Citation>B. '
 'Adhikari, J. Bozilovic, M. Diebold, J. D. Schwarz, J. Hofstetter, M. '
 'Schr&#xf6;der, M. Wanior, A. Narain, M. Vogt, N. Dudvarski Stankovic, A. '
 'Baluapuri, L. Sch&#xf6;nemann, L. Eing, P. Bhandare, B. Kuster, A. '
 'Schlosser, S. Heinzlmeir, C. Sotriffer, S. Knapp, E. Wolf, Nat. Chem. Biol. '
 '2020, 16, 1179&#x2013;1188, '
 'https://doi.org/10.1038/s41589&#x2010;020&#x2010;00652&#x2010;y.</Citation></Reference><Reference><Citation>B. '
 'Nabet, J. M. Roberts, D. L. Buckley, J. Paulk, S. Dastjerdi, A. Yang, A. L. '
 'Leggett, M. A. Erb, M. A. Lawlor, A. Souza, T. G. Scott, S. Vittori, J. A. '
 'Perry, J. Qi, G. E. Winter, K.&#x2010;K. Wong, N. S. Gray, J. E. Bradner, '
 'Nat. Chem. Biol. 2018, 14, 431&#x2013;441, '
 'https://doi.org/10.1038/s41589&#x2010;018&#x2010;0021&#x2010;8.</Citation></Reference><Reference><Citation>H. '
 'Kang, S. Hasselbeck, K. Ta&#x161;kova, N. Wang, L. N. v. Oosten, R. Mrowka, '
 'J. Utikal, M. A. Andrade&#x2010;Navarro, J. Wang, S. W&#xf6;lfl, X. Cheng, '
 'Eur. J. Med. Chem. 2023, 257, 115513, '
 'https://doi.org/10.1016/j.ejmech.2023.115513.</Citation></Reference><Reference><Citation>Y. '
 'Dabiri, R. A. Gama&#x2010;Brambila, K. Ta&#x161;kova, K. Herold, S. Reuter, '
 'J. Adjaye, J. Utikal, R. Mrowka, J. Wang, M. A. Andrade&#x2010;Navarro, X. '
 'Cheng, iScience 2019, 12, 168&#x2013;181, '
 'https://doi.org/10.1016/j.isci.2019.01.012.</Citation></Reference><Reference><Citation>X. '
 'Cheng, H. Yoshida, D. Raoofi, S. Saleh, H. Alborzinia, F. Wenke, A. '
 'G&#xf6;hring, S. Reuter, N. Mah, H. Fuchs, M. A. Andrade&#x2010;Navarro, J. '
 'Adjaye, S. Gul, J. Utikal, R. Mrowka, S. W&#xf6;lfl, J. Med. Chem. 2015, 58, '
 '5742&#x2013;5750, '
 'https://doi.org/10.1021/acs.jmedchem.5b00226.</Citation></Reference><Reference><Citation>X. '
 'Cheng, E. Dimou, H. Alborzinia, F. Wenke, A. G&#xf6;hring, S. Reuter, N. '
 'Mah, H. Fuchs, M. A. Andrade&#x2010;Navarro, J. Adjaye, S. Gul, C. Harms, J. '
 'Utikal, E. Klipp, R. Mrowka, S. W&#xf6;lfl, J. Med. Chem. 2015, 58, '
 '4976&#x2013;4983, '
 'https://doi.org/10.1021/acs.jmedchem.5b00144.</Citation></Reference><Reference><Citation>M. '
 "Gabut, P. Samavarchi&#x2010;Tehrani, X. Wang, V. Slobodeniuc, D. O'Hanlon, "
 'H.&#x2010;K. Sung, M. Alvarez, S. Talukder, Q. Pan, E. O. Mazzoni, , S. '
 'Nedelec, H. Wichterle, K. Woltjen, T. R. Hughes, , P. W. Zandstra, A. Nagy, '
 'J. L. Wrana, , B. J. Blencowe, Cell 2011, 147, 132&#x2013;146, '
 'https://doi.org/10.1016/j.cell.2011.08.023.</Citation></Reference><Reference><Citation>H. '
 'Hadjivassiliou, O. S. Rosenberg, C. Guthrie, RNA (New York, N.Y.) 2014, 20, '
 '656&#x2013;669, '
 'https://doi.org/10.1261/rna.042838.113.</Citation></Reference><Reference><Citation>M. '
 'Pettersson, C. M. Crews, Drug Discovery Today: Technologies 2019, 31, '
 '15&#x2013;27, '
 'https://doi.org/10.1016/j.ddtec.2019.01.002.</Citation></Reference><Reference><Citation>M. '
 'J. Henley, A. N. Koehler, Nat. Rev. Drug Discovery 2021, 20, 669&#x2013;688, '
 'https://doi.org/10.1038/s41573&#x2010;021&#x2010;00199&#x2010;0.</Citation></Reference><Reference><Citation>D. '
 'Weerakoon, R. J. Carbajo, L. De Maria, C. Tyrchan, H. Zhao, J. Chem. '
 'Information Modeling 2022, 62, 340&#x2013;349, '
 'https://doi.org/10.1021/acs.jcim.1c01036.</Citation></Reference><Reference><Citation>M. '
 'Altinbay, J. Wang, J. Chen, D. Sch&#xe4;fer, M. Sprang, B. Blagojevic, S. '
 'W&#xf6;lfl, M. A. Andrade&#x2010;Navarro, I. Dikic, S. Knapp, X. Cheng, '
 'Nucleic Acids Res. 2024, 52, 11587&#x2013;11601, '
 'https://doi.org/10.1093/nar/gkae798.</Citation></Reference><Reference><Citation>Y. '
 'Guo, X. Mao, L. Xiong, A. Xia, J. You, G. Lin, C. Wu, L. Huang, Y. Wang, S. '
 'Yang, Angew. Chem. Int. Ed. 2021, 60, 8760&#x2013;8765, '
 'https://doi.org/10.1002/anie.202017200.</Citation></Reference><Reference><Citation>J. '
 'L. Meidner, A. F. Frey, R. A. Zimmermann, M. O. Sabin, Z. Nidoieva, A. C. '
 'Weldert, S. N. Hoba, M. W. Krone, F. Barthels, Angew. Chem. Int. Ed. 2024, '
 '63, e202403792, '
 'https://doi.org/10.1002/anie.202403792.</Citation></Reference><Reference><Citation>Z. '
 'Na, B. Peng, S. Ng, S. Pan, J.&#x2010;S. Lee, H.&#x2010;M. Shen, S. Q. Yao, '
 'Angew. Chem. Int. Ed. 2015, 54, 2515&#x2013;2519, '
 'https://doi.org/10.1002/anie.201410678.</Citation></Reference><Reference><Citation>S. '
 'Hasselbeck, J. Wang, Z. Bai, T. H&#xfc;fner, G. Hummer, P. Grote, X. Cheng, '
 'J. Med. Chem. 2025, 68, 22633&#x2013;22649, '
 'https://doi.org/10.1021/acs.jmedchem.5c01609.</Citation></Reference><Reference><Citation>S. '
 'D. Edmondson, B. Yang, C. Fallan, Bioorg. Med. Chem. Lett. 2019, 29, '
 '1555&#x2013;1564, '
 'https://doi.org/10.1016/j.bmcl.2019.04.030.</Citation></Reference><Reference><Citation>A. '
 'Negi, A. S. Voisin&#x2010;Chiret, ChemBioChem 2022, 23, e202100689, '
 'https://doi.org/10.1002/cbic.202100689.</Citation></Reference><Reference><Citation>J.&#x2010;H. '
 'Min, H. Yang, M. Ivan, F. Gertler, W. G. Kaelin, N. P. Pavletich, Science '
 '2002, 296, 1886&#x2013;1889, '
 'https://doi.org/10.1126/science.1073440.</Citation></Reference><Reference><Citation>H. '
 'E. Nicholson, Z. Tariq, B. E. Housden, R. B. Jennings, L. A. Stransky, N. '
 'Perrimon, S. Signoretti, I. S. Harris, J. E. Endress, W. G. Kaelin Jr, Sci. '
 'Signaling 2019, 12, eaay0482, '
 'https://doi.org/10.1126/scisignal.aay0482.</Citation></Reference><Reference><Citation>M. '
 'E. Rogalska, E. Mancini, S. Bonnal, A. Gohr, B. M. Dunyak, N. Arecco, P. G. '
 'Smith, F. H. Vaillancourt, J. Valc&#xe1;rcel, Science 2024, 386, '
 '551&#x2013;560, '
 'https://doi.org/10.1126/science.adn8105.</Citation></Reference><Reference><Citation>X. '
 'Liu, A. Ciulli, ACS Cent. Sci. 2023, 9, 1269&#x2013;1284, '
 'https://doi.org/10.1021/acscentsci.3c00395.</Citation></Reference><Reference><Citation>S. '
 'Singh, W. Tian, Z. C. Severance, S. K. Chaudhary, V. Anokhina, B. Mondal, R. '
 'Pergu, P. Singh, U. Dhawa, S. Singha, A. Choudhary, Chem. Soc. Rev. 2023, '
 '52, 5485&#x2013;5515, '
 'https://doi.org/10.1039/D2CS00943A.</Citation></Reference><Reference><Citation>C. '
 'V. Dang, E. P. Reddy, K. M. Shokat, L. Soucek, Nat. Rev. Cancer 2017, 17, '
 '502&#x2013;508, '
 'https://doi.org/10.1038/nrc.2017.36.</Citation></Reference><Reference><Citation>J. '
 'S. Lazo, E. R. Sharlow, Annu. Rev. Pharmacol. Toxicol. 2016, 56, '
 '23&#x2013;40, '
 'https://doi.org/10.1146/annurev&#x2010;pharmtox&#x2010;010715&#x2010;103440.</Citation></Reference><Reference><Citation>G. '
 'L. Verdine, L. D. Walensky, Clin. Cancer Res. 2007, 13, 7264&#x2013;7270, '
 'https://doi.org/10.1158/1078&#x2010;0432.CCR&#x2010;07&#x2010;2184.</Citation></Reference><Reference><Citation>X. '
 'Xie, T. Yu, X. Li, N. Zhang, L. J. Foster, C. Peng, W. Huang, G. He, Signal '
 'Transduct. Target. Ther. 2023, 8, 335, '
 'https://doi.org/10.1038/s41392&#x2010;023&#x2010;01589&#x2010;z.</Citation></Reference><Reference><Citation>A. '
 'L. Hopkins, C. R. Groom, Nat. Rev. Drug Discovery 2002, 1, 727&#x2013;730, '
 'https://doi.org/10.1038/nrd892.</Citation></Reference><Reference><Citation>H. '
 'Cui, M. Stilgenbauer, A. N. Koehler, Annu. Rev. Cancer Biol. 2024, '
 '8:395&#x2013;415, '
 'https://doi.org/10.1146/annurev&#x2010;cancerbio&#x2010;062722&#x2010;012209 '
 '.</Citation></Reference><Reference><Citation>Q. Bai, T. Xu, J. Huang, H. '
 'P&#xe9;rez&#x2010;S&#xe1;nchez, Drug Discovery Today 2024, 29, 104024, '
 'https://doi.org/10.1016/j.drudis.2024.104024.</Citation></Reference><Reference><Citation>C. '
 'Isert, K. Atz, G. Schneider, Curr. Opin. Struct. Biol. 2023, 79, 102548, '
 'https://doi.org/10.1016/j.sbi.2023.102548.</Citation></Reference><Reference><Citation>M. '
 'D. Cheeseman, N. E. A. Chessum, C. S. Rye, A. E. Pasqua, M. J. Tucker, B. '
 'Wilding, L. E. Evans, S. Lepri, M. Richards, S. Y. Sharp, S. Ali, M. '
 "Rowlands, L. O'Fee, A. Miah, A. Hayes, A. T. Henley, M. Powers, R. te Poele, "
 'E. De Billy, L. Pellegrino, F. Raynaud, R. Burke, R. L. M. van Montfort, S. '
 'A. Eccles, P. Workman, K. Jones, J. Med. Chem. 2017, 60, 180&#x2013;201, '
 'https://doi.org/10.1021/acs.jmedchem.6b01055.</Citation></Reference><Reference><Citation>X. '
 'Han, C. Wang, C. Qin, W. Xiang, E. Fernandez&#x2010;Salas, C.&#x2010;Y. '
 'Yang, M. Wang, L. Zhao, T. Xu, K. Chinnaswamy, J. Delproposto, J. Stuckey, '
 'S. Wang, J. Med. Chem. 2019, 62, 941&#x2013;964, '
 'https://doi.org/10.1021/acs.jmedchem.8b01631.</Citation></Reference><Reference><Citation>B. '
 'Maji, S. A. Gangopadhyay, M. Lee, M. Shi, P. Wu, R. Heler, B. Mok, D. Lim, '
 'S. U. Siriwardena, B. Paul, V. Dan&#x10d;&#xed;k, A. Vetere, M. F. Mesleh, '
 'L. A. Marraffini, D. R. Liu, P. A. Clemons, B. K. Wagner, A. Choudhary, Cell '
 '2019, 177, 1067&#x2013;1079.e19, '
 'https://doi.org/10.1016/j.cell.2019.04.009.</Citation></Reference><Reference><Citation>X. '
 'Cheng, Mol. Ther. 2020, 28, 2635&#x2013;2641, '
 'https://doi.org/10.1016/j.ymthe.2020.08.014.</Citation></Reference><Reference><Citation>P. '
 'Cimmperman, L. Baranauskien&#x117;, S. Jachimovi&#x10d;i&#x16b;t&#x117;, J. '
 'Jachno, J. Torresan, V. Michailovien&#x117;, J. Matulien&#x117;, J. '
 'Sereikait&#x117;, V. Bumelis, D. Matulis, Biophys. J. 2008, 95, '
 '3222&#x2013;3231, '
 'https://doi.org/10.1529/biophysj.108.134973.</Citation></Reference><Reference><Citation>L. '
 'Reinhard, H. Mayerhofer, A. Geerlof, J. Mueller&#x2010;Dieckmann, M. S. '
 'Weiss, Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2013, 69, '
 '209&#x2013;214, '
 'https://doi.org/10.1107/S1744309112051858.</Citation></Reference><Reference><Citation>H. '
 'Ummethum, S. Hamperl, Front. Genet. 2020, 11, 450, '
 'https://doi.org/10.3389/fgene.2020.00450.</Citation></Reference><Reference><Citation>K. '
 'J. Roux, D. I. Kim, M. Raida, B. Burke, J. Cell Biol. 2012, 196, '
 '801&#x2013;810, '
 'https://doi.org/10.1083/jcb.201112098.</Citation></Reference><Reference><Citation>G. '
 'Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman, J. '
 'Comput.&#x2010;Aided Mol. Des. 2013, 27, 221&#x2013;234, '
 'https://doi.org/10.1007/s10822&#x2010;013&#x2010;9644&#x2010;8.</Citation></Reference><Reference><Citation>T. '
 'A. Halgren, J. Chem. Inf. Model. 2009, 49, 377&#x2013;389, '
 'https://doi.org/10.1021/ci800324m.</Citation></Reference><Reference><Citation>R. '
 'A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. '
 'Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. '
 'Francis, P. S. Shenkin, J. Med. Chem. 2004, 47, 1739&#x2013;1749, '
 'https://doi.org/10.1021/jm0306430.</Citation></Reference><Reference><Citation>R. '
 'A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. '
 'Halgren, P. C. Sanschagrin, D. T. Mainz, J. Med. Chem. 2006, 49, '
 '6177&#x2013;6196, '
 'https://doi.org/10.1021/jm051256o.</Citation></Reference><Reference><Citation>C. '
 'S. Hughes, S. Moggridge, T. M&#xfc;ller, P. H. Sorensen, G. B. Morin, J. '
 'Krijgsveld, Nat. Protoc. 2019, 14, 68&#x2013;85, '
 'https://doi.org/10.1038/s41596&#x2010;018&#x2010;0082&#x2010;x.</Citation></Reference><Reference><Citation>C. '
 'B. Messner, V. Demichev, D. Wendisch, L. Michalick, M. White, A. Freiwald, '
 'K. Textoris&#x2010;Taube, S. I. Vernardis, A.&#x2010;S. Egger, M. Kreidl, D. '
 'Ludwig, C. Kilian, F. Agostini, A. Zelezniak, C. Thibeault, M. Pfeiffer, S. '
 'Hippenstiel, A. Hocke, C. von Kalle, A. Campbell, C. Hayward, D. J. '
 'Porteous, R. E. Marioni, C. Langenberg, K. S. Lilley, W. M. Kuebler, M. '
 'M&#xfc;lleder, C. Drosten, N. Suttorp, M. Witzenrath, et&#xa0;al. Cell '
 'Systems 2020, 11, 11&#x2013;24.e4, '
 'https://doi.org/10.1016/j.cels.2020.05.012.</Citation></Reference><Reference><Citation>V. '
 'Demichev, C. B. Messner, S. I. Vernardis, K. S. Lilley, M. Ralser, Nat. '
 'Methods 2020, 17, 41&#x2013;44, '
 'https://doi.org/10.1038/s41592&#x2010;019&#x2010;0638&#x2010;x.</Citation></Reference><Reference><Citation>S. '
 'Tyanova, T. Temu, P. Sinitcyn, A. Carlson, M. Y. Hein, T. Geiger, M. Mann, '
 'J. Cox, Nat. Methods 2016, 13, 731&#x2013;740, '
 'https://doi.org/10.1038/nmeth.3901.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation '
 'Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID '
 'Version="1">41238805</PMID><DateCompleted><Year>2025</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>11</Month><Day>17</Day></DateRevised><Article '
 'PubModel="Electronic"><Journal><ISSN '
 'IssnType="Electronic">2045-2322</ISSN><JournalIssue '
 'CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Scientific '
 'reports</Title><ISOAbbreviation>Sci '
 'Rep</ISOAbbreviation></Journal><ArticleTitle>Astaxanthin inhibits '
 'hepatocellular carcinoma by targeting USP39-mediated &#x3b2;-catenin '
 'stabilization through '
 'deubiquitination.</ArticleTitle><Pagination><StartPage>40034</StartPage><MedlinePgn>40034</MedlinePgn></Pagination><ELocationID '
 'EIdType="pii" ValidYN="Y">40034</ELocationID><ELocationID EIdType="doi" '
 'ValidYN="Y">10.1038/s41598-025-23891-2</ELocationID><Abstract><AbstractText>Although '
 'studies suggest that astaxanthin exerts anticancer effects through '
 'Wnt/&#x3b2;-catenin pathway, its therapeutic target remains unclear. The '
 'deubiquitinase USP39 may be a potential target due to its ability to '
 'regulate this pathway in hepatocellular carcinoma (HCC). This study aims to '
 'identify the role and underlying mechanism of USP39 in the anti-HCC effects '
 'of astaxanthin via Wnt/&#x3b2;-catenin pathway. In vitro, HepG2 and HuH7 '
 'cell lines were treated with astaxanthin, and cell proliferation was '
 'assessed using CCK-8, colony formation, and EdU assays. Western blot and '
 'real-time qPCR were used to analyze the expression of USP39, '
 '&#x3b2;-catenin, and Cyclin D1. Co-immunoprecipitation and ubiquitination '
 'assays were performed to confirm the interaction between USP39 and '
 '&#x3b2;-catenin. In vivo, HuH7 xenografts in nude mice were established to '
 'evaluate tumor growth following astaxanthin treatment. Immunohistochemistry '
 'and western blot analyses were conducted to examine the expression of USP39, '
 '&#x3b2;-catenin, Cyclin D1, and Ki-67 in tumor tissues. Astaxanthin '
 'treatment significantly reduced cell viability and colony formation, '
 'accompanied by decreased levels of USP39, &#x3b2;-catenin, and Cyclin D1, '
 'and increased phosphorylated &#x3b2;-catenin. Astaxanthin-induced USP39 '
 'inhibition promoted &#x3b2;-catenin ubiquitination and degradation, thereby '
 'blocking Wnt/&#x3b2;-catenin pathway activation. &#x3b2;-catenin '
 'overexpression partially rescued the anti-tumor effects of USP39 knockdown. '
 'Astaxanthin significantly suppressed tumor growth, inhibited the expression '
 'of USP39, &#x3b2;-catenin, and Cyclin D1, and reduced the proportion of '
 'Ki-67-positive cells in tumor tissues. Astaxanthin inhibits HCC through '
 'USP39-mediated ubiquitination of &#x3b2;-catenin, providing novel insights '
 'into its anticancer mechanism. These findings highlight the potential of '
 'targeting USP39 for HCC therapy, especially in combination with '
 'astaxanthin.</AbstractText><CopyrightInformation>&#xa9; 2025. The '
 'Author(s).</CopyrightInformation></Abstract><AuthorList '
 'CompleteYN="Y"><Author ValidYN="Y" '
 'EqualContrib="Y"><LastName>Li</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key '
 'Laboratory of Translational Tumor Medicine in Fujian Province, Putian '
 'University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" '
 'EqualContrib="Y"><LastName>Xu</LastName><ForeName>Huiyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Chen</LastName><ForeName>Ruoxi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Huang</LastName><ForeName>Xianzhi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Lin</LastName><ForeName>Zequan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Wang</LastName><ForeName>Shouan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key '
 'Laboratory of Translational Tumor Medicine in Fujian Province, Putian '
 'University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Han</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key '
 'Laboratory of Translational Tumor Medicine in Fujian Province, Putian '
 'University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Li</LastName><ForeName>Jinqiu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Central '
 'Laboratory, The Affiliated Hospital of Putian University, No. 999 Dongzhen '
 'East Road, Licheng District, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Lin</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharmaceutical '
 'and Medical Technology College, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Qi</LastName><ForeName>Yamei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pharmaceutical '
 'and Medical Technology College, Putian University, Putian, 351100, Fujian, '
 'China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Song</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cancer '
 'Research Center, School of Medicine, Xiamen University, Xiamen, 361100, '
 'Fujian, China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Song</LastName><ForeName>Conghua</ForeName><Initials>C</Initials><Identifier '
 'Source="ORCID">0000-0002-1908-0640</Identifier><AffiliationInfo><Affiliation>School '
 'of Basic Medicine, Putian University, Putian, 351100, Fujian, China. '
 'kesongs@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central '
 'Laboratory, The Affiliated Hospital of Putian University, No. 999 Dongzhen '
 'East Road, Licheng District, Putian, 351100, Fujian, China. '
 'kesongs@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList '
 'CompleteYN="Y"><Grant><GrantID>82200676</GrantID><Agency>National Natural '
 'Science Foundation of '
 'China</Agency><Country/></Grant><Grant><GrantID>2022J05258</GrantID><Agency>Natural '
 'Science Foundation of Fujian Province of '
 'China</Agency><Country/></Grant><Grant><GrantID>2024GGA089</GrantID><Agency>the '
 'Fujian Provincial Health Technology '
 'Project</Agency><Country/></Grant><Grant><GrantID>2024106</GrantID><Agency>the '
 'Collaborative Project Between the Hospital and College of Putian '
 'University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType '
 'UI="D016428">Journal '
 'Article</PublicationType></PublicationTypeList><ArticleDate '
 'DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci '
 'Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance '
 'UI="D051176">beta '
 'Catenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8XPW32PR7I</RegistryNumber><NameOfSubstance '
 'UI="C005948">astaxanthine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance '
 'UI="D024341">Xanthophylls</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC '
 '3.4.19.12</RegistryNumber><NameOfSubstance UI="C579218">USP39 protein, '
 'human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC '
 '3.4.19.12</RegistryNumber><NameOfSubstance UI="D064570">Ubiquitin-Specific '
 'Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance '
 'UI="C495270">CTNNB1 protein, '
 'human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName '
 'UI="D006801" '
 'MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D006528" MajorTopicYN="Y">Carcinoma, '
 'Hepatocellular</DescriptorName><QualifierName UI="Q000188" '
 'MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" '
 'MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" '
 'MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D051176" MajorTopicYN="Y">beta Catenin</DescriptorName><QualifierName '
 'UI="Q000378" '
 'MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName '
 'UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName '
 'UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName '
 'UI="Q000473" '
 'MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D000818" '
 'MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName><QualifierName '
 'UI="Q000187" MajorTopicYN="N">drug '
 'effects</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D024341" MajorTopicYN="N">Xanthophylls</DescriptorName><QualifierName '
 'UI="Q000494" '
 'MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D051379" '
 'MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D049109" MajorTopicYN="N">Cell '
 'Proliferation</DescriptorName><QualifierName UI="Q000187" '
 'MajorTopicYN="N">drug '
 'effects</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D060449" MajorTopicYN="N">Wnt Signaling '
 'Pathway</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug '
 'effects</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D008819" MajorTopicYN="N">Mice, '
 'Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" '
 'MajorTopicYN="N">Cell Line, '
 'Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D064570" MajorTopicYN="Y">Ubiquitin-Specific '
 'Proteases</DescriptorName><QualifierName UI="Q000378" '
 'MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" '
 'MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor '
 'Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D056945" MajorTopicYN="N">Hep G2 '
 'Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D015972" MajorTopicYN="N">Gene Expression Regulation, '
 'Neoplastic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug '
 'effects</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D008297" '
 'MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList '
 'Owner="NOTNLM"><Keyword MajorTopicYN="N">Astaxanthin</Keyword><Keyword '
 'MajorTopicYN="N">Hepatocellular carcinoma</Keyword><Keyword '
 'MajorTopicYN="N">Proliferation</Keyword><Keyword '
 'MajorTopicYN="N">USP39</Keyword><Keyword '
 'MajorTopicYN="N">Ubiquitination</Keyword><Keyword '
 'MajorTopicYN="N">&#x392;-catenin</Keyword></KeywordList><CoiStatement>Declarations. '
 'Ethical statement: The animal study protocol was approved by the '
 'Institutional Animal Care and Use Committee of Putian University (IACUC No. '
 '2021-005). All methods were performed in accordance with the relevant '
 'guidelines and regulations. The study is reported in accordance with ARRIVE '
 'guidelines 2.0. for animal research. Competing interests: The authors '
 'declare no competing '
 'interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate '
 'PubStatus="received"><Year>2025</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>15</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>14</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId '
 'IdType="pubmed">41238805</ArticleId><ArticleId '
 'IdType="pmc">PMC12618549</ArticleId><ArticleId '
 'IdType="doi">10.1038/s41598-025-23891-2</ArticleId><ArticleId '
 'IdType="pii">10.1038/s41598-025-23891-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li, '
 'J. et al. Astaxanthin inhibits proliferation and induces apoptosis of human '
 'hepatocellular carcinoma cells via inhibition of Nf-Kappab P65 and '
 'Wnt/beta-catenin in vitro. <i>Mar. Drugs</i>. <b>13</b>(10), '
 '6064&#x2013;6081. 10.3390/md13106064 (2015).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC4626679</ArticleId><ArticleId '
 'IdType="pubmed">26404320</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajos-Michniewicz, '
 'A. &amp; Czyz, M. WNT/beta-catenin signaling in hepatocellular carcinoma: '
 'the aberrant activation, pathogenic roles, and therapeutic opportunities. '
 '<i>Genes Dis.</i><b>11</b>(2), 727&#x2013;746. 10.1016/j.gendis.2023.02.050 '
 '(2024).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC10491942</ArticleId><ArticleId '
 'IdType="pubmed">37692481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakrania, '
 'A., To, J., Zheng, G. &amp; Bhat, M. Targeting Wnt-beta-catenin signaling '
 'pathway for hepatocellular carcinoma nanomedicine. <i>Gastro Hep '
 'Adv.</i><b>2</b>(7), 948&#x2013;963. 10.1016/j.gastha.2023.07.012 (2023).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC11307499</ArticleId><ArticleId '
 'IdType="pubmed">39130774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, '
 'P. et al. staxanthin augmented the anti-hepatocellular carcinoma efficacy of '
 'sorafenib through the Inhibition of the JAK2/STAT3 signaling pathway and '
 'mitigation of hypoxia within the tumor microenvironment. <i>Mol. Nutr. Food '
 'Res.</i><b>68</b>(2), e2300569. 10.1002/mnfr.202300569 (2024).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">38059808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, '
 'P. et al. Dietary supplementation with astaxanthin enhances anti-tumor '
 'immune response and aids the enhancement of molecularly targeted therapy for '
 'hepatocellular carcinoma. <i>Food Funct.</i><b>14</b>(18), 8309&#x2013;8320. '
 '10.1039/d3fo02986g (2023).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">37602817</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, '
 'Y., Zhang, J., Jiang, W. &amp; Zhang, S. Astaxanthin induces angiogenesis '
 'through Wnt/beta-catenin signaling pathway. <i>Phytomedicine</i><b>22</b>, '
 '7&#x2013;8. 10.1016/j.phymed.2015.05.054 (2015). '
 '744&#x2009;&#x2013;&#x2009;51.</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">26141761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, '
 'W. et al. USP39 stabilizes beta-catenin by deubiquitination and suppressing '
 'E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression. <i>Cell. '
 'Death Dis.</i><b>14</b>(1), 63. 10.1038/s41419-023-05593-7 (2023).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC9883245</ArticleId><ArticleId '
 'IdType="pubmed">36707504</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, '
 'X. et al. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of '
 'ZEB1 ubiquitination and thereby determine the progression of hepatocellular '
 'carcinoma. <i>Cell. Death Differ.</i><b>28</b>(8), 2315&#x2013;2332. '
 '10.1038/s41418-021-00754-7 (2021).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC8329202</ArticleId><ArticleId '
 'IdType="pubmed">33649471</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, '
 'L., Zhu, G., Johns, E. M. &amp; Yang, X. TRIM11 activates the proteasome and '
 'promotes overall protein degradation by regulating USP14. <i>Nat. '
 'Commun.</i><b>9</b>(1), 1223. 10.1038/s41467-018-03499-z (2018).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC5964324</ArticleId><ArticleId '
 'IdType="pubmed">29581427</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieau, '
 'G. et al. ICG-001, an inhibitor of the beta-Catenin and cAMP response '
 'element-binding protein dependent gene transcription, decreases '
 'proliferation but enhances migration of osteosarcoma cells. '
 '<i>Pharmaceuticals</i>. <b>14</b>(5). 10.3390/ph14050421 '
 '(2021).</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC8147379</ArticleId><ArticleId '
 'IdType="pubmed">34062831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan, '
 'P. &amp; Kulik, L. M. Hepatocellular carcinoma: new developments. <i>Clin. '
 'Liver Dis.</i><b>27</b>(1), 85&#x2013;102. 10.1016/j.cld.2022.08.004 '
 '(2023).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">36400469</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangro, '
 'B., Sarobe, P., Hervas-Stubbs, S. &amp; Melero, I. Advances in immunotherapy '
 'for hepatocellular carcinoma. <i>Nat. Rev. Gastroenterol. '
 'Hepatol.</i><b>18</b>(8), 525&#x2013;543. 10.1038/s41575-021-00438-0 '
 '(2021).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC8042636</ArticleId><ArticleId '
 'IdType="pubmed">33850328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussagy, '
 'C. U. Advances in microbial astaxanthin production. <i>Adv. Appl. '
 'Microbiol.</i><b>128</b>, 105&#x2013;120. 10.1016/bs.aambs.2024.05.001 '
 '(2024).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">39059842</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida, '
 'Y. et al. Astaxanthin: Past, present, and future. <i>Mar. Drugs</i>. '
 '<b>21</b>(10). 10.3390/md21100514 '
 '(2023).</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC10608541</ArticleId><ArticleId '
 'IdType="pubmed">37888449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, '
 'G., Ni, Y., Nagata, N., Xu, L. &amp; Ota, T. Micronutrient antioxidants and '
 'nonalcoholic fatty liver disease. <i>Int. J. Mol. Sci.</i><b>17</b>(9). '
 '10.3390/ijms17091379 (2016).</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC5037659</ArticleId><ArticleId '
 'IdType="pubmed">27563875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavitha, '
 'K., Kowshik, J., Kishore, T. K., Baba, A. B. &amp; Nagini, S. Astaxanthin '
 'inhibits NF-kappaB and Wnt/beta-catenin signaling pathways via inactivation '
 'of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of '
 'oral cancer. <i>Biochim. Biophys. Acta</i>. <b>1830</b>(10), '
 '4433&#x2013;4444. 10.1016/j.bbagen.2013.05.032 (2013).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">23726989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, '
 'S. H. &amp; Kim, H. Inhibitory effect of Astaxanthin on gene expression '
 'changes in Helicobacter pylori-Infected human gastric epithelial cells. '
 '<i>Nutrients</i><b>13</b>(12). 10.3390/nu13124281 '
 '(2021).</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC8708722</ArticleId><ArticleId '
 'IdType="pubmed">34959833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, '
 'P., Yue, H., Tang, Q., Wang, Y. &amp; Xue, C. Astaxanthin slows down '
 'skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment '
 'by modulating the gut microbiota. <i>Food Funct.</i><b>15</b>(2), '
 '543&#x2013;558. 10.1039/d3fo04633h (2024).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">38116809</ArticleId></ArticleIdList></Reference><Reference><Citation>Si, '
 'P. &amp; Zhu, C. Biological and neurological activities of astaxanthin '
 '(review). <i>Mol. Med. Rep.</i><b>26</b>(4). 10.3892/mmr.2022.12816 '
 '(2022).</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC9435021</ArticleId><ArticleId '
 'IdType="pubmed">35946443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi, '
 'D. N. &amp; Jena, G. B. Astaxanthin intervention ameliorates '
 'cyclophosphamide-induced oxidative stress, DNA damage and early '
 'hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. '
 '<i>Mutat. Res.</i><b>696</b>(1), 69&#x2013;80. '
 '10.1016/j.mrgentox.2009.12.014 (2010).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">20038455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida, '
 'Y., Nawaz, A., Hecht, K. &amp; Tobe, K. Astaxanthin as a novel mitochondrial '
 'regulator: A new aspect of carotenoids, beyond antioxidants. '
 '<i>Nutrients</i><b>14</b>(1). 10.3390/nu14010107 '
 '(2021).</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC8746862</ArticleId><ArticleId '
 'IdType="pubmed">35010981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, '
 'X., Li, W., Dou, X., Nan, D. &amp; He, G. Astaxanthin encapsulated in '
 'biodegradable calcium alginate microspheres for the treatment of '
 'hepatocellular carcinoma in vitro. <i>Appl. Biochem. '
 'Biotechnol.</i><b>191</b>(2), 511&#x2013;527. 10.1007/s12010-019-03174-z '
 '(2020).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">31811643</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, '
 'X. et al. Changes in cell ultrastructure and inhibition of JAK1/STAT3 '
 'signaling pathway in CBRH-7919 cells with astaxanthin. <i>Toxicol. Mech. '
 'Methods</i>. <b>22</b>(9), 679&#x2013;686. 10.3109/15376516.2012.717119 '
 '(2012).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">22889354</ArticleId></ArticleIdList></Reference><Reference><Citation>He, '
 'S. &amp; Tang, S. WNT/beta-catenin signaling in the development of liver '
 'cancers. <i>Biomed. Pharmacother</i>. <b>132</b>, 110851. '
 '10.1016/j.biopha.2020.110851 (2020).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pubmed">33080466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, '
 'C. et al. Astaxanthin prevents osteoarthritis by blocking Rspo2-mediated '
 'Wnt/beta-catenin signaling in chondrocytes and abolishing Rspo2-related '
 'inflammatory factors in macrophages. <i>Aging</i>. <b>15</b>(12), '
 '5775&#x2013;5797. 10.18632/aging.204837 (2023).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC10333078</ArticleId><ArticleId '
 'IdType="pubmed">37354487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, '
 'J. et al. USP39 promotes hepatocellular carcinogenesis through regulating '
 'alternative splicing in cooperation with SRSF6/HNRNPC. <i>Cell. Death '
 'Dis.</i><b>14</b>(10), 670. 10.1038/s41419-023-06210-3 (2023).\n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC10567755</ArticleId><ArticleId '
 'IdType="pubmed">37821439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation '
 'Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID '
 'Version="1">40990019</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>26</Day></DateRevised><Article '
 'PubModel="Electronic-eCollection"><Journal><ISSN '
 'IssnType="Electronic">1664-3224</ISSN><JournalIssue '
 'CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers '
 'in immunology</Title><ISOAbbreviation>Front '
 'Immunol</ISOAbbreviation></Journal><ArticleTitle>USP39 at the crossroads of '
 'cancer immunity: regulating immune evasion and immunotherapy response '
 'through RNA splicing and ubiquitin '
 'signaling.</ArticleTitle><Pagination><StartPage>1665775</StartPage><MedlinePgn>1665775</MedlinePgn></Pagination><ELocationID '
 'EIdType="pii" ValidYN="Y">1665775</ELocationID><ELocationID EIdType="doi" '
 'ValidYN="Y">10.3389/fimmu.2025.1665775</ELocationID><Abstract><AbstractText>Deubiquitinating '
 'enzymes (DUBs) are responsible for the removal of ubiquitin from substrates, '
 'thereby antagonizing ubiquitination and regulating a multitude of biological '
 'pathways including cell cycle progression, signal transduction, and '
 'transcriptional regulation. Ubiquitin Specific Protease-39 (USP39), a '
 'pivotal member of the ubiquitin-specific protease family, is intricately '
 'linked to innumerable pathophysiological processes. In this review, we first '
 'provide an overview of the specific structural domains and biological '
 'functions of USP39, with a particular focus on its role in DNA damage repair '
 'and RNA splicing processes. Then, we delineate the function of USP39 in '
 'maintaining epithelial morphology, resistance to viral infection, vascular '
 'remodeling, and pathological states. Moreover, we particularly focus on the '
 'aberrant expression of USP39 in various cancers and its effect on cancer '
 'markers, as well as on the regulatory role of USP39 in tumor progression. In '
 'conclusion, a comprehensive analysis of the structural domains and '
 'functional properties of USP39, a detailed investigation into its '
 'interaction mechanisms with diverse substrates, and the accelerated '
 'development of related inhibitors will provide a novel theoretical '
 'foundation for the treatment of numerous diseases, including tumors. '
 'Importantly, targeting USP39 may overcome resistance to checkpoint '
 'inhibitors, offering a promising approach to enhance cancer immunotherapy '
 'efficacy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Zhou, '
 'Li, Sun, Wang, Niu, Gao, Zhang, Chen, Li, Zhao, Mao, Xu, Shi and '
 'He.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author '
 'ValidYN="Y" '
 'EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Feilong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y" '
 'EqualContrib="Y"><LastName>Li</LastName><ForeName>Xinhao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y" '
 'EqualContrib="Y"><LastName>Sun</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y" '
 'EqualContrib="Y"><LastName>Wang</LastName><ForeName>Yizhu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Niu</LastName><ForeName>Kaiyi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Gao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiaqi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Chen</LastName><ForeName>Tianyi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Li</LastName><ForeName>Yunxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weijie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Mao</LastName><ForeName>Binyue</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department '
 "of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, "
 "Xi'an,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author "
 'ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiyang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>General '
 "Surgery Department, Fuyang Fifth People's Hospital, "
 'Fuyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>Shi</LastName><ForeName>Yanlong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, Fuyang Hospital of Anhui Medical University, '
 'Fuyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author '
 'ValidYN="Y"><LastName>He</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>General '
 'Surgery Department, The Second Affiliated Hospital of Nanjing Medical '
 'University, '
 'Nanjing,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType '
 'UI="D016428">Journal Article</PublicationType><PublicationType '
 'UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate '
 'DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front '
 'Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC '
 '3.4.19.12</RegistryNumber><NameOfSubstance UI="D064570">Ubiquitin-Specific '
 'Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC '
 '3.4.19.12</RegistryNumber><NameOfSubstance UI="C579218">USP39 protein, '
 'human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance '
 'UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName '
 'UI="D006801" '
 'MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName '
 'UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName '
 'UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName '
 'UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName '
 'UI="Q000235" '
 'MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D015398" MajorTopicYN="N">Signal '
 'Transduction</DescriptorName><QualifierName UI="Q000276" '
 'MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D064570" MajorTopicYN="Y">Ubiquitin-Specific '
 'Proteases</DescriptorName><QualifierName UI="Q000378" '
 'MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" '
 'MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" '
 'MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000737" '
 'MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D000818" '
 'MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName '
 'UI="Q000379" '
 'MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D012326" MajorTopicYN="Y">RNA '
 'Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D025801" MajorTopicYN="Y">Ubiquitin</DescriptorName><QualifierName '
 'UI="Q000378" '
 'MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D057131" MajorTopicYN="Y">Immune '
 'Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D019139" MajorTopicYN="Y">Tumor '
 'Escape</DescriptorName></MeshHeading><MeshHeading><DescriptorName '
 'UI="D054875" '
 'MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList '
 'Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA damage repair</Keyword><Keyword '
 'MajorTopicYN="N">RNA splicing</Keyword><Keyword '
 'MajorTopicYN="N">USP39</Keyword><Keyword '
 'MajorTopicYN="N">cancers</Keyword><Keyword '
 'MajorTopicYN="N">deubiquitylation</Keyword><Keyword '
 'MajorTopicYN="N">immunotherapy</Keyword><Keyword '
 'MajorTopicYN="N">regulation</Keyword><Keyword '
 'MajorTopicYN="N">structure</Keyword></KeywordList><CoiStatement>The authors '
 'declare that the research was conducted in the absence of any commercial or '
 'financial relationships that could be construed as a potential conflict of '
 'interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate '
 'PubStatus="received"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate '
 'PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>13</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId '
 'IdType="pubmed">40990019</ArticleId><ArticleId '
 'IdType="pmc">PMC12450694</ArticleId><ArticleId '
 'IdType="doi">10.3389/fimmu.2025.1665775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gross '
 'S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with '
 'kinase inhibitors. J Clin Invest. (2015) 125:1780&#x2013;9. doi:&#xa0; '
 '10.1172/jci76094, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1172/jci76094</ArticleId><ArticleId '
 'IdType="pmc">PMC4463189</ArticleId><ArticleId '
 'IdType="pubmed">25932675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevissen '
 'TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. '
 'Annu Rev Biochem. (2017) 86:159&#x2013;92. doi:&#xa0; '
 '10.1146/annurev-biochem-061516-044916, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1146/annurev-biochem-061516-044916</ArticleId><ArticleId '
 'IdType="pubmed">28498721</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts '
 'JZ, Crawford N, Longley DB. The role of ubiquitination in apoptosis and '
 'necroptosis. Cell Death Differ. (2022) 29:272&#x2013;84. doi:&#xa0; '
 '10.1038/s41418-021-00922-9, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41418-021-00922-9</ArticleId><ArticleId '
 'IdType="pmc">PMC8817035</ArticleId><ArticleId '
 'IdType="pubmed">34912054</ArticleId></ArticleIdList></Reference><Reference><Citation>Komander '
 'D, Rape M. The ubiquitin code. Annu Rev Biochem. (2012) 81:203&#x2013;29. '
 'doi:&#xa0; 10.1146/annurev-biochem-060310-170328, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1146/annurev-biochem-060310-170328</ArticleId><ArticleId '
 'IdType="pubmed">22524316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko '
 'A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. (1998) '
 '67:425&#x2013;79. doi:&#xa0; 10.1146/annurev.biochem.67.1.425, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1146/annurev.biochem.67.1.425</ArticleId><ArticleId '
 'IdType="pubmed">9759494</ArticleId></ArticleIdList></Reference><Reference><Citation>Buetow '
 'L, Huang DT. Structural insights into the catalysis and regulation of E3 '
 'ubiquitin ligases. Nat Rev Mol Cell Biol. (2016) 17:626&#x2013;42. '
 'doi:&#xa0; 10.1038/nrm.2016.91, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/nrm.2016.91</ArticleId><ArticleId '
 'IdType="pmc">PMC6211636</ArticleId><ArticleId '
 'IdType="pubmed">27485899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sewduth '
 'RN, Baietti MF, Sablina AA. Cracking the monoubiquitin code of genetic '
 'diseases. Int J Mol Sci. (2020) 21:3036. doi:&#xa0; 10.3390/ijms21093036, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3390/ijms21093036</ArticleId><ArticleId '
 'IdType="pmc">PMC7246618</ArticleId><ArticleId '
 'IdType="pubmed">32344852</ArticleId></ArticleIdList></Reference><Reference><Citation>Baur '
 'R, Rape M. Getting close: insight into the structure and function of '
 'K11/K48-branched ubiquitin chains. Structure. (2020) 28:1&#x2013;3. '
 'doi:&#xa0; 10.1016/j.str.2019.12.004, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.str.2019.12.004</ArticleId><ArticleId '
 'IdType="pubmed">31951536</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Turcu '
 'FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of '
 'ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. (2009) '
 '78:363&#x2013;97. doi:&#xa0; 10.1146/annurev.biochem.78.082307.091526, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1146/annurev.biochem.78.082307.091526</ArticleId><ArticleId '
 'IdType="pmc">PMC2734102</ArticleId><ArticleId '
 'IdType="pubmed">19489724</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang '
 'J, Saad Y, Lei T, Wang J, Qi D, Yang Q, et al. MCP-induced protein 1 '
 'deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB '
 'signaling. J Exp Med. (2010) 207:2959&#x2013;73. doi:&#xa0; '
 '10.1084/jem.20092641, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1084/jem.20092641</ArticleId><ArticleId '
 'IdType="pmc">PMC3005225</ArticleId><ArticleId '
 'IdType="pubmed">21115689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermanns '
 'T, Pichlo C, Woiwode I, Klopffleisch K, Witting KF, Ovaa H, et al. A family '
 'of unconventional deubiquitinases with modular chain specificity '
 'determinants. Nat Commun. (2018) 9:799. doi:&#xa0; '
 '10.1038/s41467-018-03148-5, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41467-018-03148-5</ArticleId><ArticleId '
 'IdType="pmc">PMC5824887</ArticleId><ArticleId '
 'IdType="pubmed">29476094</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao '
 'Y, Zhou D, Wang P, Yang M, Jiang N. Ubiquitin specific peptidase 11 as a '
 'novel therapeutic target for cancer management. Cell Death Discov. (2022) '
 '8:292. doi:&#xa0; 10.1038/s41420-022-01083-5, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41420-022-01083-5</ArticleId><ArticleId '
 'IdType="pmc">PMC9205893</ArticleId><ArticleId '
 'IdType="pubmed">35715413</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu '
 'F, Chen J, Li K, Li H, Zhu Y, Zhai Y, et al. Ubiquitination and '
 'deubiquitination in cancer: from mechanisms to novel therapeutic approaches. '
 'Mol Cancer. (2024) 23:148. doi:&#xa0; 10.1186/s12943-024-02046-3, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12943-024-02046-3</ArticleId><ArticleId '
 'IdType="pmc">PMC11270804</ArticleId><ArticleId '
 'IdType="pubmed">39048965</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun '
 'T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer '
 'metabolism. Mol Cancer. (2020) 19:146. doi:&#xa0; '
 '10.1186/s12943-020-01262-x, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12943-020-01262-x</ArticleId><ArticleId '
 'IdType="pmc">PMC7529510</ArticleId><ArticleId '
 'IdType="pubmed">33004065</ArticleId></ArticleIdList></Reference><Reference><Citation>Georges '
 'A, Gros P, Fodil N. USP15: a review of its implication in immune and '
 'inflammatory processes and tumor progression. Genes Immun. (2021) '
 '22:12&#x2013;23. doi:&#xa0; 10.1038/s41435-021-00125-9, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41435-021-00125-9</ArticleId><ArticleId '
 'IdType="pubmed">33824497</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder '
 'NA, Silva GM. Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and '
 'oxidative stress response. J Biol Chem. (2021) 297:101077. doi:&#xa0; '
 '10.1016/j.jbc.2021.101077, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.jbc.2021.101077</ArticleId><ArticleId '
 'IdType="pmc">PMC8424594</ArticleId><ArticleId '
 'IdType="pubmed">34391779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennerich '
 'D, Kubaichuk K, Kietzmann T. DUBs, hypoxia, and cancer. Trends Cancer. '
 '(2019) 5:632&#x2013;53. doi:&#xa0; 10.1016/j.trecan.2019.08.005, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.trecan.2019.08.005</ArticleId><ArticleId '
 'IdType="pubmed">31706510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura '
 'H. Ubiquitin-specific proteases (USPs) and metabolic disorders. Int J Mol '
 'Sci. (2023) 24:3219. doi:&#xa0; 10.3390/ijms24043219, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3390/ijms24043219</ArticleId><ArticleId '
 'IdType="pmc">PMC9966627</ArticleId><ArticleId '
 'IdType="pubmed">36834633</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao '
 'H, Xi Z, Dai J, Xue J, Guan X, Zhao L, et al. Drug resistance mechanisms and '
 'treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in '
 'cancers: new directions and therapeutic options. Mol Cancer. (2024) 23:88. '
 'doi:&#xa0; 10.1186/s12943-024-02005-y, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12943-024-02005-y</ArticleId><ArticleId '
 'IdType="pmc">PMC11067278</ArticleId><ArticleId '
 'IdType="pubmed">38702734</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao '
 'H, Yin J, Ji C, Yu X, Xue J, Guan X, et al. Targeting ubiquitin specific '
 'proteases (USPs) in cancer immunotherapy: from basic research to preclinical '
 'application. J Exp Clin Cancer Res. (2023) 42:225. doi:&#xa0; '
 '10.1186/s13046-023-02805-y, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s13046-023-02805-y</ArticleId><ArticleId '
 'IdType="pmc">PMC10472646</ArticleId><ArticleId '
 'IdType="pubmed">37658402</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang '
 'H, Zhang X, Lao M, Sun K, He L, Xu J, et al. Targeting ubiquitin-specific '
 'protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of '
 'pancreatic cancer. Cell Death Differ. (2023) 30:560&#x2013;75. doi:&#xa0; '
 '10.1038/s41418-022-01102-z, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41418-022-01102-z</ArticleId><ArticleId '
 'IdType="pmc">PMC9950432</ArticleId><ArticleId '
 'IdType="pubmed">36539510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mines '
 'MA, Goodwin JS, Limbird LE, Cui FF, Fan GH. Deubiquitination of CXCR4 by '
 'USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis '
 'but not ERK ativation. J Biol Chem. (2009) 284:5742&#x2013;52. doi:&#xa0; '
 '10.1074/jbc.M808507200, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1074/jbc.M808507200</ArticleId><ArticleId '
 'IdType="pmc">PMC2645827</ArticleId><ArticleId '
 'IdType="pubmed">19106094</ArticleId></ArticleIdList></Reference><Reference><Citation>Felle '
 'M, Joppien S, N&#xe9;meth A, Diermeier S, Thalhammer V, Dobner T, et al. The '
 'USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 and '
 'regulates the stability of UHRF1. Nucleic Acids Res. (2011) '
 '39:8355&#x2013;65. doi:&#xa0; 10.1093/nar/gkr528, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1093/nar/gkr528</ArticleId><ArticleId '
 'IdType="pmc">PMC3201865</ArticleId><ArticleId '
 'IdType="pubmed">21745816</ArticleId></ArticleIdList></Reference><Reference><Citation>Scicinski '
 'J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, et al. The development of '
 'RRx-001, A novel nitric-oxide-mediated epigenetically active anticancer '
 'agent. Redox Biol. (2015) 5:422. doi:&#xa0; 10.1016/j.redox.2015.09.035, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.redox.2015.09.035</ArticleId><ArticleId '
 'IdType="pubmed">28162292</ArticleId></ArticleIdList></Reference><Reference><Citation>van '
 'Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM, Medema RH. Usp39 is '
 'essential for mitotic spindle checkpoint integrity and controls mRNA-levels '
 'of aurora B. Cell Cycle. (2008) 7:2710&#x2013;9. doi:&#xa0; '
 '10.4161/cc.7.17.6553, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.4161/cc.7.17.6553</ArticleId><ArticleId '
 'IdType="pubmed">18728397</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuchi '
 'S. Three classes of C2H2 zinc finger proteins. Cell Mol Life Sci. (2001) '
 '58:625&#x2013;35. doi:&#xa0; 10.1007/pl00000885, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/pl00000885</ArticleId><ArticleId '
 'IdType="pmc">PMC11146492</ArticleId><ArticleId '
 'IdType="pubmed">11361095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhouche '
 'N, Syvanen M, Kado CI. The origin of prokaryotic C2H2 zinc finger '
 'regulators. Trends Microbiol. (2000) 8:77&#x2013;81. doi:&#xa0; '
 '10.1016/s0966-842x(99)01679-0, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/s0966-842x(99)01679-0</ArticleId><ArticleId '
 'IdType="pubmed">10664601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe '
 'SA, Nekludova L, Pabo CO. DNA recognition by Cys2His2 zinc finger proteins. '
 'Annu Rev Biophys Biomol Struct. (2000) 29:183&#x2013;212. doi:&#xa0; '
 '10.1146/annurev.biophys.29.1.183, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1146/annurev.biophys.29.1.183</ArticleId><ArticleId '
 'IdType="pubmed">10940247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayer '
 'KJ, Segal DJ. Keep your fingers off my DNA: protein-protein interactions '
 'mediated by C2H2 zinc finger domains. Cell Biochem Biophys. (2008) '
 '50:111&#x2013;31. doi:&#xa0; 10.1007/s12013-008-9008-5, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s12013-008-9008-5</ArticleId><ArticleId '
 'IdType="pubmed">18253864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjivassiliou '
 'H, Rosenberg OS, Guthrie C. The crystal structure of S. cerevisiae Sad1, a '
 'catalytically inactive deubiquitinase that is broadly required for pre-mRNA '
 'splicing. Rna. (2014) 20:656&#x2013;69. doi:&#xa0; 10.1261/rna.042838.113, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1261/rna.042838.113</ArticleId><ArticleId '
 'IdType="pmc">PMC3988567</ArticleId><ArticleId '
 'IdType="pubmed">24681967</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang '
 'Y, Shen X. Ubiquitin carboxyl-terminal hydrolases: involvement in cancer '
 'progression and clinical implications. Cancer Metastasis Rev. (2017) '
 '36:669&#x2013;82. doi:&#xa0; 10.1007/s10555-017-9702-0, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s10555-017-9702-0</ArticleId><ArticleId '
 'IdType="pubmed">29080080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura-Yoshida '
 'C, Mochida K, Kanno SI, Matsuo I. USP39 is essential for mammalian '
 'epithelial morphogenesis through upregulation of planar cell polarity '
 'components. Commun Biol. (2022) 5:378. doi:&#xa0; '
 '10.1038/s42003-022-03254-7, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s42003-022-03254-7</ArticleId><ArticleId '
 'IdType="pmc">PMC9018712</ArticleId><ArticleId '
 'IdType="pubmed">35440748</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng '
 'Y, Guo J, Sun T, Fu Y, Zheng H, Dong C, et al. USP39 serves as a '
 'deubiquitinase to stabilize STAT1 and sustains type I IFN-induced antiviral '
 'immunity. J Immunol. (2020) 205:3167&#x2013;78. doi:&#xa0; '
 '10.4049/jimmunol.1901384, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.4049/jimmunol.1901384</ArticleId><ArticleId '
 'IdType="pubmed">33127822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'W, Lei Y, Zhang G, Li X, Yuan J, Li T, et al. USP39 stabilizes '
 '&#x3b2;-catenin by deubiquitination and suppressing E3 ligase TRIM26 '
 'pre-mRNA maturation to promote HCC progression. Cell Death Dis. (2023) '
 '14:63. doi:&#xa0; 10.1038/s41419-023-05593-7, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41419-023-05593-7</ArticleId><ArticleId '
 'IdType="pmc">PMC9883245</ArticleId><ArticleId '
 'IdType="pubmed">36707504</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao '
 'Y, Chen X, Hu W, Ma W, Di Q, Tang H, et al. USP39-mediated deubiquitination '
 'of Cyclin B1 promotes tumor cell proliferation and glioma progression. '
 'Transl Oncol. (2023) 34:101713. doi:&#xa0; 10.1016/j.tranon.2023.101713, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.tranon.2023.101713</ArticleId><ArticleId '
 'IdType="pmc">PMC10302533</ArticleId><ArticleId '
 'IdType="pubmed">37302347</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi '
 'Y, Lee Y, Kim JS, Zhang P, Kim J. USP39-mediated non-proteolytic control of '
 'ETS2 suppresses nuclear localization and activity. Biomolecules. (2023) '
 '13:1475. doi:&#xa0; 10.3390/biom13101475, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3390/biom13101475</ArticleId><ArticleId '
 'IdType="pmc">PMC10604658</ArticleId><ArticleId '
 'IdType="pubmed">37892157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao '
 'C, Li S, Che J, Liu D, Mao X, Rao H. The ubiquitin ligase UBR4 and the '
 'deubiquitylase USP5 modulate the stability of DNA mismatch repair protein '
 'MLH1. J Biol Chem. (2024) 300:107592. doi:&#xa0; 10.1016/j.jbc.2024.107592, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.jbc.2024.107592</ArticleId><ArticleId '
 'IdType="pmc">PMC11375253</ArticleId><ArticleId '
 'IdType="pubmed">39032648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartek '
 'J, Falck J, Lukas J. CHK2 kinase&#x2013;a busy messenger. Nat Rev Mol Cell '
 'Biol. (2001) 2:877&#x2013;86. doi:&#xa0; 10.1038/35103059, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/35103059</ArticleId><ArticleId '
 'IdType="pubmed">11733767</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohgaki '
 'M, Hakem A, Halaby MJ, Bohgaki T, Li Q, Bissey PA, et al. The E3 ligase '
 'PIRH2 polyubiquitylates CHK2 and regulates its turnover. Cell Death Differ. '
 '(2013) 20:812&#x2013;22. doi:&#xa0; 10.1038/cdd.2013.7, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/cdd.2013.7</ArticleId><ArticleId '
 'IdType="pmc">PMC3647240</ArticleId><ArticleId '
 'IdType="pubmed">23449389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu '
 'J, Chen Y, Geng G, Li L, Yin P, Nowsheen S, et al. USP39 regulates DNA '
 'damage response and chemo-radiation resistance by deubiquitinating and '
 'stabilizing CHK2. Cancer Lett. (2019) 449:114&#x2013;24. doi:&#xa0; '
 '10.1016/j.canlet.2019.02.015, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.canlet.2019.02.015</ArticleId><ArticleId '
 'IdType="pubmed">30771428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang '
 'HC, Lee YI, Shin JH, Andrabi SA, Chi Z, Gagn&#xe9; JP, et al. Iduna is a '
 'poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA '
 'damage. Proc Natl Acad Sci U S A. (2011) 108:14103&#x2013;8. doi:&#xa0; '
 '10.1073/pnas.1108799108, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1073/pnas.1108799108</ArticleId><ArticleId '
 'IdType="pmc">PMC3161609</ArticleId><ArticleId '
 'IdType="pubmed">21825151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim '
 'JJ, Lee SY, Hwang Y, Kim S, Chung JM, Park S, et al. USP39 promotes '
 'non-homologous end-joining repair by poly(ADP-ribose)-induced liquid '
 'demixing. Nucleic Acids Res. (2021) 49:11083&#x2013;102. doi:&#xa0; '
 '10.1093/nar/gkab892, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1093/nar/gkab892</ArticleId><ArticleId '
 'IdType="pmc">PMC8565343</ArticleId><ArticleId '
 'IdType="pubmed">34614178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson '
 'ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem. '
 '(2020) 89:359&#x2013;88. doi:&#xa0; 10.1146/annurev-biochem-091719-064225, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1146/annurev-biochem-091719-064225</ArticleId><ArticleId '
 'IdType="pubmed">31794245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen '
 'TH, Galej WP, Bai XC, Savva CG, Newman AJ, Scheres SH, et al. The '
 'architecture of the spliceosomal U4/U6.U5 tri-snRNP. Nature. (2015) '
 '523:47&#x2013;52. doi:&#xa0; 10.1038/nature14548, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/nature14548</ArticleId><ArticleId '
 'IdType="pmc">PMC4536768</ArticleId><ArticleId '
 'IdType="pubmed">26106855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan '
 'R, Yan C, Bai R, Wang L, Huang M, Wong CC, et al. The 3.8 &#xc5; structure '
 'of the U4/U6.U5 tri-snRNP: Insights into spliceosome assembly and catalysis. '
 'Science. (2016) 351:466&#x2013;75. doi:&#xa0; 10.1126/science.aad6466, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1126/science.aad6466</ArticleId><ArticleId '
 'IdType="pubmed">26743623</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman '
 'AJ, Norman C. U5 snRNA interacts with exon sequences at 5&#x2019; and '
 '3&#x2019; splice sites. Cell. (1992) 68:743&#x2013;54. doi:&#xa0; '
 '10.1016/0092-8674(92)90149-7, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/0092-8674(92)90149-7</ArticleId><ArticleId '
 'IdType="pubmed">1739979</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarova '
 'OV, Makarov EM, L&#xfc;hrmann R. The 65 and 110 kDa SR-related proteins of '
 'the U4/U6.U5 tri-snRNP are essential for the assembly of mature '
 'spliceosomes. EMBO J. (2001) 20:2553&#x2013;63. doi:&#xa0; '
 '10.1093/emboj/20.10.2553, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1093/emboj/20.10.2553</ArticleId><ArticleId '
 'IdType="pmc">PMC125249</ArticleId><ArticleId '
 'IdType="pubmed">11350945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan '
 'GX, Li Y, Chen W, Huang H, Zhang R, Chen C, et al. The spliceosome component '
 'Usp39 controls B cell development by regulating immunoglobulin gene '
 'rearrangement. Cell Rep. (2022) 38:110338. doi:&#xa0; '
 '10.1016/j.celrep.2022.110338, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.celrep.2022.110338</ArticleId><ArticleId '
 'IdType="pubmed">35139388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding '
 'R, Yu X, Hu Z, Dong Y, Huang H, Zhang Y, et al. Lactate modulates RNA '
 'splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T '
 'cells. Immunity. (2024) 57:528&#x2013;540.e526. doi:&#xa0; '
 '10.1016/j.immuni.2024.01.019, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.immuni.2024.01.019</ArticleId><ArticleId '
 'IdType="pubmed">38417442</ArticleId></ArticleIdList></Reference><Reference><Citation>Marasco '
 'LE, Kornblihtt AR. The physiology of alternative splicing. Nat Rev Mol Cell '
 'Biol. (2023) 24:242&#x2013;54. doi:&#xa0; 10.1038/s41580-022-00545-z, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41580-022-00545-z</ArticleId><ArticleId '
 'IdType="pubmed">36229538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui '
 'D, Wang Z, Dang Q, Wang J, Qin J, Song J, et al. Spliceosome component Usp39 '
 'contributes to hepatic lipid homeostasis through the regulation of '
 'autophagy. Nat Commun. (2023) 14:7032. doi:&#xa0; '
 '10.1038/s41467-023-42461-6, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41467-023-42461-6</ArticleId><ArticleId '
 'IdType="pmc">PMC10624899</ArticleId><ArticleId '
 'IdType="pubmed">37923718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheeseman '
 'IM, Anderson S, Jwa M, Green EM, Kang J, Yates JR, 3rd, et al. '
 'Phospho-regulation of kinetochore-microtubule attachments by the Aurora '
 'kinase Ipl1p. Cell. (2002) 111:163&#x2013;72. doi:&#xa0; '
 '10.1016/s0092-8674(02)00973-x, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/s0092-8674(02)00973-x</ArticleId><ArticleId '
 'IdType="pubmed">12408861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecuit '
 'T, Lenne PF. Cell surface mechanics and the control of cell shape, tissue '
 'patterns and morphogenesis. Nat Rev Mol Cell Biol. (2007) 8:633&#x2013;44. '
 'doi:&#xa0; 10.1038/nrm2222, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/nrm2222</ArticleId><ArticleId '
 'IdType="pubmed">17643125</ArticleId></ArticleIdList></Reference><Reference><Citation>An '
 'MJ, Kim CH, Nam GY, Kim DH, Rhee S, Cho SJ, et al. Transcriptome analysis '
 'for UVB-induced phototoxicity in mouse retina. Environ Toxicol. (2018) '
 '33:52&#x2013;62. doi:&#xa0; 10.1002/tox.22494, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1002/tox.22494</ArticleId><ArticleId '
 'IdType="pubmed">29044990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura-Yoshida '
 'C, Mochida K, Ellwanger K, Niehrs C, Matsuo I. Fate specification of neural '
 'plate border by canonical wnt signaling and grhl3 is crucial for neural tube '
 'closure. EBioMedicine. (2015) 2:513&#x2013;27. doi:&#xa0; '
 '10.1016/j.ebiom.2015.04.012, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.ebiom.2015.04.012</ArticleId><ArticleId '
 'IdType="pmc">PMC4535158</ArticleId><ArticleId '
 'IdType="pubmed">26288816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura-Yoshida '
 'C, Mochida K, Nakaya MA, Mizutani T, Matsuo I. Cytoplasmic localization of '
 'GRHL3 upon epidermal differentiation triggers cell shape change for '
 'epithelial morphogenesis. Nat Commun. (2018) 9:4059. doi:&#xa0; '
 '10.1038/s41467-018-06171-8, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41467-018-06171-8</ArticleId><ArticleId '
 'IdType="pmc">PMC6170465</ArticleId><ArticleId '
 'IdType="pubmed">30283008</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby '
 'AC, George SJ. Proliferation, migration, matrix turnover, and death of '
 'smooth muscle cells in native coronary and vein graft atherosclerosis. Curr '
 'Opin Cardiol. (1996) 11:574&#x2013;82. doi:&#xa0; '
 '10.1097/00001573-199611000-00004, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1097/00001573-199611000-00004</ArticleId><ArticleId '
 'IdType="pubmed">8968671</ArticleId></ArticleIdList></Reference><Reference><Citation>He '
 'S, Zhong W, Yin L, Wang Y, Qiu Z, Song G. High expression of '
 'ubiquitin-specific peptidase 39 is associated with the development of '
 'vascular remodeling. Mol Med Rep. (2017) 15:2567&#x2013;73. doi:&#xa0; '
 '10.3892/mmr.2017.6297, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/mmr.2017.6297</ArticleId><ArticleId '
 'IdType="pmc">PMC5428656</ArticleId><ArticleId '
 'IdType="pubmed">28447728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr '
 'A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, et al. Dynamics '
 'and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol. (2012) '
 '91:524&#x2013;32. doi:&#xa0; 10.1016/j.ejcb.2011.09.005, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.ejcb.2011.09.005</ArticleId><ArticleId '
 'IdType="pubmed">22018664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen '
 'X, Tian L, Zhang L, Gao W, Yu M, Li Z, et al. Deubiquitinase USP39 promotes '
 'SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope '
 'protein. Antiviral Res. (2024) 221:105790. doi:&#xa0; '
 '10.1016/j.antiviral.2023.105790, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.antiviral.2023.105790</ArticleId><ArticleId '
 'IdType="pubmed">38158131</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan '
 'J, Zhao X, Xiao Y, Wu H, Di Q, Wu Z, et al. USP39 regulates '
 'NF-&#x3ba;B-mediated inflammatory responses through deubiquitinating '
 'K48-linked I&#x3ba;B&#x3b1;. J Immunol. (2023) 210:640&#x2013;52. doi:&#xa0; '
 '10.4049/jimmunol.2200603, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.4049/jimmunol.2200603</ArticleId><ArticleId '
 'IdType="pubmed">36651806</ArticleId></ArticleIdList></Reference><Reference><Citation>Filatova '
 'EV, Shadrina MI, Alieva A, Kolacheva AA, Slominsky PA, Ugrumov MV. '
 'Expression analysis of genes of ubiquitin-proteasome protein degradation '
 'system in MPTP-induced mice models of early stages of Parkinson&#x2019;s '
 'disease. Dokl Biochem Biophys. (2014) 456:116&#x2013;8. doi:&#xa0; '
 '10.1134/s1607672914030107, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1134/s1607672914030107</ArticleId><ArticleId '
 'IdType="pubmed">24993970</ArticleId></ArticleIdList></Reference><Reference><Citation>\n'
 'Yu X, Yang L, Li J, Li W, Li D, Wang R, et al. \n'
 '<i>De novo</i> and inherited SETD1A variants in early-onset epilepsy. '
 'Neurosci Bull. (2019) 35:1045&#x2013;57. doi:&#xa0; '
 '10.1007/s12264-019-00400-w, PMID: \n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s12264-019-00400-w</ArticleId><ArticleId '
 'IdType="pmc">PMC6864154</ArticleId><ArticleId '
 'IdType="pubmed">31197650</ArticleId></ArticleIdList></Reference><Reference><Citation>Geh '
 'D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential '
 'therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol '
 'Hepatol. (2022) 19:257&#x2013;73. doi:&#xa0; 10.1038/s41575-021-00568-5, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41575-021-00568-5</ArticleId><ArticleId '
 'IdType="pubmed">35022608</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet '
 'JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. '
 'Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. (2022) '
 '19:151&#x2013;72. doi:&#xa0; 10.1038/s41571-021-00573-2, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41571-021-00573-2</ArticleId><ArticleId '
 'IdType="pubmed">34764464</ArticleId></ArticleIdList></Reference><Reference><Citation>Li '
 'X, Yuan J, Song C, Lei Y, Xu J, Zhang G, et al. Deubiquitinase USP39 and E3 '
 'ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine '
 'the progression of hepatocellular carcinoma. Cell Death Differ. (2021) '
 '28:2315&#x2013;32. doi:&#xa0; 10.1038/s41418-021-00754-7, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41418-021-00754-7</ArticleId><ArticleId '
 'IdType="pmc">PMC8329202</ArticleId><ArticleId '
 'IdType="pubmed">33649471</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao '
 'Y, Li L, Liu H, Song Y. High expression of ubiquitin-specific protease 39 '
 'and its roles in prognosis in patients with hepatocellular carcinoma. Evid '
 'Based Complement Alternat Med. (2021) 2021:6233175. doi:&#xa0; '
 '10.1155/2021/6233175, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1155/2021/6233175</ArticleId><ArticleId '
 'IdType="pmc">PMC8723855</ArticleId><ArticleId '
 'IdType="pubmed">34987596</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong '
 'X, Liu Z, Zhang E, Zhang P, Wang Y, Hang J, et al. USP39 promotes '
 'tumorigenesis by stabilizing and deubiquitinating SP1 protein in '
 'hepatocellular carcinoma. Cell Signal. (2021) 85:110068. doi:&#xa0; '
 '10.1016/j.cellsig.2021.110068, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.cellsig.2021.110068</ArticleId><ArticleId '
 'IdType="pubmed">34197957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni '
 'W, Bian S, Zhu M, Song Q, Zhang J, Xiao M, et al. Identification and '
 'validation of ubiquitin-specific proteases as a novel prognostic signature '
 'for hepatocellular carcinoma. Front Oncol. (2021) 11:629327. doi:&#xa0; '
 '10.3389/fonc.2021.629327, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3389/fonc.2021.629327</ArticleId><ArticleId '
 'IdType="pmc">PMC7949004</ArticleId><ArticleId '
 'IdType="pubmed">33718205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan '
 'X, Sun X, Shi X, Jiang C, Yu D, Zhang W, et al. USP39 regulates the growth '
 'of SMMC-7721 cells via FoxM1. Exp Ther Med. (2017) 13:1506&#x2013;13. '
 'doi:&#xa0; 10.3892/etm.2017.4115, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/etm.2017.4115</ArticleId><ArticleId '
 'IdType="pmc">PMC5377580</ArticleId><ArticleId '
 'IdType="pubmed">28413501</ArticleId></ArticleIdList></Reference><Reference><Citation>\n'
 'Yuan X, Sun X, Shi X, Jiang C, Yu D, Zhang W, et al. USP39 promotes the '
 'growth of human hepatocellular carcinoma <i>in vitro</i> and in <i>vivo</i>\n'
 '. Oncol Rep. (2015) 34:823&#x2013;32. doi:&#xa0; 10.3892/or.2015.4065, '
 'PMID: \n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/or.2015.4065</ArticleId><ArticleId '
 'IdType="pubmed">26081192</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu '
 'Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, et al. Plk1-dependent '
 'phosphorylation of FoxM1 regulates a transcriptional programme required for '
 'mitotic progression. Nat Cell Biol. (2008) 10:1076&#x2013;82. doi:&#xa0; '
 '10.1038/ncb1767, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/ncb1767</ArticleId><ArticleId '
 'IdType="pmc">PMC2882053</ArticleId><ArticleId '
 'IdType="pubmed">19160488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong '
 'L, Yu L, Li H, Shi L, Luo Z, Zhao H, et al. An NAD(+)-dependent deacetylase '
 'SIRT7 promotes HCC development through deacetylation of USP39. iScience. '
 '(2020) 23:101351. doi:&#xa0; 10.1016/j.isci.2020.101351, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.isci.2020.101351</ArticleId><ArticleId '
 'IdType="pmc">PMC7387830</ArticleId><ArticleId '
 'IdType="pubmed">32711345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim '
 'T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, et al. p53 regulates '
 'epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. '
 'J Exp Med. (2011) 208:875&#x2013;83. doi:&#xa0; 10.1084/jem.20110235, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1084/jem.20110235</ArticleId><ArticleId '
 'IdType="pmc">PMC3092351</ArticleId><ArticleId '
 'IdType="pubmed">21518799</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao '
 'C, Sun J, Zhang D, Guo X, Xie L, Li X, et al. The long intergenic noncoding '
 'RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing '
 'protein HuR to increase levels of &#x3b2;-catenin in HCC cells. '
 'Gastroenterology. (2015) 148:415&#x2013;426.e418. doi:&#xa0; '
 '10.1053/j.gastro.2014.10.012, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1053/j.gastro.2014.10.012</ArticleId><ArticleId '
 'IdType="pubmed">25449213</ArticleId></ArticleIdList></Reference><Reference><Citation>Horani '
 'A, Ustione A, Huang T, Firth AL, Pan J, Gunsten SP, et al. Establishment of '
 'the early cilia preassembly protein complex during motile ciliogenesis. Proc '
 'Natl Acad Sci U S A. (2018) 115:E1221&#x2013;e1228. doi:&#xa0; '
 '10.1073/pnas.1715915115, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1073/pnas.1715915115</ArticleId><ArticleId '
 'IdType="pmc">PMC5819421</ArticleId><ArticleId '
 'IdType="pubmed">29358401</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu '
 'Y, Wu Q, Sun T, Huang J, Han G, Han H. DNAAF5 promotes hepatocellular '
 'carcinoma Malignant progression by recruiting USP39 to improve PFKL protein '
 'stability. Front Oncol. (2022) 12:1032579. doi:&#xa0; '
 '10.3389/fonc.2022.1032579, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3389/fonc.2022.1032579</ArticleId><ArticleId '
 'IdType="pmc">PMC9582515</ArticleId><ArticleId '
 'IdType="pubmed">36276075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng '
 'J, Wu S, Tang M, Xi S, Wang Y, Ren J, et al. USP39 promotes hepatocellular '
 'carcinogenesis through regulating alternative splicing in cooperation with '
 'SRSF6/HNRNPC. Cell Death Dis. (2023) 14:670. doi:&#xa0; '
 '10.1038/s41419-023-06210-3, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41419-023-06210-3</ArticleId><ArticleId '
 'IdType="pmc">PMC10567755</ArticleId><ArticleId '
 'IdType="pubmed">37821439</ArticleId></ArticleIdList></Reference><Reference><Citation>Li '
 'Y, Sharma A, Schmidt-Wolf IGH. Evolving insights into the improvement of '
 'adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical '
 'spectrum of lung cancer. Mol Cancer. (2024) 23:80. doi:&#xa0; '
 '10.1186/s12943-023-01926-4, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12943-023-01926-4</ArticleId><ArticleId '
 'IdType="pmc">PMC11040940</ArticleId><ArticleId '
 'IdType="pubmed">38659003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin '
 'Z, Xiong L, Lin Q. Ubiquitin-specific protease 39 is overexpressed in human '
 'lung cancer and promotes tumor cell proliferation. vitro. Mol Cell Biochem. '
 '(2016) 422:97&#x2013;107. doi:&#xa0; 10.1007/s11010-016-2809-8, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s11010-016-2809-8</ArticleId><ArticleId '
 'IdType="pubmed">27629785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan '
 'J, Zhang G, Li X, Ma Q, Cheng W, Wang W, et al. Knocking down USP39 Inhibits '
 'the Growth and Metastasis of Non-Small-Cell Lung Cancer Cells through '
 'Activating the p53 Pathway. Int J Mol Sci. (2020) 21:3036. doi:&#xa0; '
 '10.3390/ijms21238949, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3390/ijms21238949</ArticleId><ArticleId '
 'IdType="pmc">PMC7728369</ArticleId><ArticleId '
 'IdType="pubmed">33255748</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui '
 'F, Luo P, Wu R, Meng J. miR-381 inhibits proliferation and invasion of '
 'non-small-cell cancer cells by targeting USP39. Dis Markers. (2022) '
 '2022:2195393. doi:&#xa0; 10.1155/2022/2195393, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1155/2022/2195393</ArticleId><ArticleId '
 'IdType="pmc">PMC9420621</ArticleId><ArticleId '
 'IdType="pubmed">36046375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou '
 'W, Chen J, Wang Y. MRPL35 induces proliferation, invasion, and glutamine '
 'metabolism in NSCLC cells by upregulating SLC7A5 expression. Clin Respir J. '
 '(2024) 18:e13799. doi:&#xa0; 10.1111/crj.13799, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1111/crj.13799</ArticleId><ArticleId '
 'IdType="pmc">PMC11236733</ArticleId><ArticleId '
 'IdType="pubmed">38987867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung '
 'H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. '
 'Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality '
 'worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) '
 '71:209&#x2013;49. doi:&#xa0; 10.3322/caac.21660, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3322/caac.21660</ArticleId><ArticleId '
 'IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>\n'
 'Wang H, Ji X, Liu X, Yao R, Chi J, Liu S, et al. Lentivirus-mediated '
 'inhibition of USP39 suppresses the growth of breast cancer cells in '
 '<i>vitro</i>\n'
 '. Oncol Rep. (2013) 30:2871&#x2013;7. doi:&#xa0; 10.3892/or.2013.2798, '
 'PMID: \n'
 '</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/or.2013.2798</ArticleId><ArticleId '
 'IdType="pubmed">24126978</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu '
 'S, Liu X, Wang H, Zhou Q, Liang Y, Sui A, et al. Lentiviral vector-mediated '
 'doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative '
 'breast cancer cells. Oncol Rep. (2015) 33:2477&#x2013;83. doi:&#xa0; '
 '10.3892/or.2015.3872, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/or.2015.3872</ArticleId><ArticleId '
 'IdType="pubmed">25812575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuligina '
 'ES, Sokolenko AP, Bizin IV, Romanko AA, Zagorodnev KA, Anisimova MO, et al. '
 'Exome sequencing study of Russian breast cancer patients suggests a '
 'predisposing role for USP39. Breast Cancer Res Treat. (2020) '
 '179:731&#x2013;42. doi:&#xa0; 10.1007/s10549-019-05492-6, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s10549-019-05492-6</ArticleId><ArticleId '
 'IdType="pubmed">31754952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang '
 'Z, Liu W, Bao X, Sun T, Wang J, Li M, et al. USP39 facilitates breast cancer '
 'cell proliferation through stabilization of FOXM1. Am J Cancer Res. (2022) '
 '12:3644&#x2013;61., PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC9442023</ArticleId><ArticleId '
 'IdType="pubmed">36119839</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre '
 'LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian '
 'cancer statistics, 2018. CA Cancer J Clin. (2018) 68:284&#x2013;96. '
 'doi:&#xa0; 10.3322/caac.21456, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3322/caac.21456</ArticleId><ArticleId '
 'IdType="pmc">PMC6621554</ArticleId><ArticleId '
 'IdType="pubmed">29809280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'L, Chen T, Li X, Yan W, Lou Y, Liu Z, et al. USP39 promotes ovarian cancer '
 'Malignant phenotypes and carboplatin chemoresistance. Int J Oncol. (2019) '
 '55:277&#x2013;88. doi:&#xa0; 10.3892/ijo.2019.4818, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/ijo.2019.4818</ArticleId><ArticleId '
 'IdType="pubmed">31180526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan '
 'C, Yuan J, Xu J, Zhang G, Li X, Zhang B, et al. Ubiquitin-specific peptidase '
 '39 regulates the process of proliferation and migration of human ovarian '
 'cancer via p53/p21 pathway and EMT. Med Oncol. (2019) 36:95. doi:&#xa0; '
 '10.1007/s12032-019-1308-7, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s12032-019-1308-7</ArticleId><ArticleId '
 'IdType="pubmed">31637536</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'S, Wang Z, Li J, Qin J, Song J, Li Y, et al. Splicing factor USP39 promotes '
 'ovarian cancer Malignancy through maintaining efficient splicing of '
 'oncogenic HMGA2. Cell Death Dis. (2021) 12:294. doi:&#xa0; '
 '10.1038/s41419-021-03581-3, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41419-021-03581-3</ArticleId><ArticleId '
 'IdType="pmc">PMC7969951</ArticleId><ArticleId '
 'IdType="pubmed">33731694</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel '
 'RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) '
 '69:7&#x2013;34. doi:&#xa0; 10.3322/caac.21551, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3322/caac.21551</ArticleId><ArticleId '
 'IdType="pubmed">30620402</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing '
 'Z, Sun F, He W, Wang Z, Song X, Zhang F. Downregulation of '
 'ubiquitin-specific peptidase 39 suppresses the proliferation and induces the '
 'apoptosis of human colorectal cancer cells. Oncol Lett. (2018) '
 '15:5443&#x2013;50. doi:&#xa0; 10.3892/ol.2018.8061, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/ol.2018.8061</ArticleId><ArticleId '
 'IdType="pmc">PMC5844003</ArticleId><ArticleId '
 'IdType="pubmed">29556295</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan '
 'X, Sun X, Shi X, Wang H, Wu G, Jiang C, et al. USP39 promotes colorectal '
 'cancer growth and metastasis through the Wnt/&#x3b2;-catenin pathway. Oncol '
 'Rep. (2017) 37:2398&#x2013;404. doi:&#xa0; 10.3892/or.2017.5454, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/or.2017.5454</ArticleId><ArticleId '
 'IdType="pubmed">28259917</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan '
 'J, Li X, Zhang G, Cheng W, Wang W, Lei Y, et al. USP39 mediates '
 'p21-dependent proliferation and neoplasia of colon cancer cells by '
 'regulating the p53/p21/CDC2/cyclin B1 axis. Mol Carcinog. (2021) '
 '60:265&#x2013;78. doi:&#xa0; 10.1002/mc.23290, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1002/mc.23290</ArticleId><ArticleId '
 'IdType="pubmed">33634905</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon '
 'RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during '
 'vertebrate development. Trends Genet. (1997) 13:157&#x2013;62. doi:&#xa0; '
 '10.1016/s0168-9525(97)01093-7, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/s0168-9525(97)01093-7</ArticleId><ArticleId '
 'IdType="pubmed">9097727</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan '
 'J, Li X, Zhang Y, Zhang G, Cheng W, Wang W, et al. USP39 attenuates the '
 'antitumor activity of cisplatin on colon cancer cells dependent on p53. Cell '
 'Biol Toxicol. (2023) 39:1995&#x2013;2010. doi:&#xa0; '
 '10.1007/s10565-021-09683-0, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s10565-021-09683-0</ArticleId><ArticleId '
 'IdType="pubmed">34822033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi '
 'J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular '
 'metabolism in gliomas - an emerging landscape of actionable co-dependency '
 'targets. Nat Rev Cancer. (2020) 20:57&#x2013;70. doi:&#xa0; '
 '10.1038/s41568-019-0226-5, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41568-019-0226-5</ArticleId><ArticleId '
 'IdType="pubmed">31806884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding '
 'K, Ji J, Zhang X, Huang B, Chen A, Zhang D, et al. RNA splicing factor USP39 '
 'promotes glioma progression by inducing TAZ mRNA maturation. Oncogene. '
 '(2019) 38:6414&#x2013;28. doi:&#xa0; 10.1038/s41388-019-0888-1, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41388-019-0888-1</ArticleId><ArticleId '
 'IdType="pmc">PMC6756117</ArticleId><ArticleId '
 'IdType="pubmed">31332287</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao '
 'Y, Ma W, Hu W, Di Q, Zhao X, Ma X, et al. Ubiquitin-specific peptidase 39 '
 'promotes human glioma cells migration and invasion by facilitating ADAM9 '
 'mRNA maturation. Mol Oncol. (2022) 16:388&#x2013;404. doi:&#xa0; '
 '10.1002/1878-0261.12958, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1002/1878-0261.12958</ArticleId><ArticleId '
 'IdType="pmc">PMC8763660</ArticleId><ArticleId '
 'IdType="pubmed">33811456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordenonsi '
 'M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo '
 'transducer TAZ confers cancer stem cell-related traits on breast cancer '
 'cells. Cell. (2011) 147:759&#x2013;72. doi:&#xa0; '
 '10.1016/j.cell.2011.09.048, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.cell.2011.09.048</ArticleId><ArticleId '
 'IdType="pubmed">22078877</ArticleId></ArticleIdList></Reference><Reference><Citation>Roychaudhuri '
 'R, Hergrueter AH, Polverino F, Laucho-Contreras ME, Gupta K, Borregaard N, '
 'et al. ADAM9 is a novel product of polymorphonuclear neutrophils: regulation '
 'of expression and contributions to extracellular matrix protein degradation '
 'during acute lung injury. J Immunol. (2014) 193:2469&#x2013;82. doi:&#xa0; '
 '10.4049/jimmunol.1303370, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.4049/jimmunol.1303370</ArticleId><ArticleId '
 'IdType="pmc">PMC4134955</ArticleId><ArticleId '
 'IdType="pubmed">25063875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu '
 'T, Lei D, Zhou J, Zhang BO. circRNA derived from CLSPN (circCLSPN) is an '
 'oncogene in human glioblastoma multiforme by regulating cell growth, '
 'migration and invasion via ceRNA pathway. J Biosci. (2021) 46:66. doi:&#xa0; '
 '10.1007/s12038-021-00185-z, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s12038-021-00185-z</ArticleId><ArticleId '
 'IdType="pubmed">34269180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'Y, Suarez ER, Kastrunes G, de Campos NSP, Abbas R, Pivetta RS, et al. '
 'Evolution of cell therapy for renal cell carcinoma. Mol Cancer. (2024) 23:8. '
 'doi:&#xa0; 10.1186/s12943-023-01911-x, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12943-023-01911-x</ArticleId><ArticleId '
 'IdType="pmc">PMC10775455</ArticleId><ArticleId '
 'IdType="pubmed">38195534</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu '
 'Y, Zhu MR, Zhang JY, Si GM, Lv JJ. Knockdown of ubiquitin&#x2212;specific '
 'peptidase 39 inhibits the Malignant progression of human renal cell '
 'carcinoma. Mol Med Rep. (2018) 17:4729&#x2013;35. doi:&#xa0; '
 '10.3892/mmr.2018.8421, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/mmr.2018.8421</ArticleId><ArticleId '
 'IdType="pubmed">29328477</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan '
 'XW, Xu D, Chen WJ, Chen JX, Chen WJ, Ye JQ, et al. USP39 promotes Malignant '
 'proliferation and angiogenesis of renal cell carcinoma by inhibiting '
 'VEGF-A(165b) alternative splicing via regulating SRSF1 and SRPK1. Cancer '
 'Cell Int. (2021) 21:486. doi:&#xa0; 10.1186/s12935-021-02161-x, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12935-021-02161-x</ArticleId><ArticleId '
 'IdType="pmc">PMC8454004</ArticleId><ArticleId '
 'IdType="pubmed">34544400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhu '
 'S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. '
 'Lancet. (2021) 398:1075&#x2013;90. doi:&#xa0; 10.1016/s0140-6736(21)00950-8, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/s0140-6736(21)00950-8</ArticleId><ArticleId '
 'IdType="pubmed">34370973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang '
 'HM, Yeh ETH. SUMO: from bench to bedside. Physiol Rev. (2020) '
 '100:1599&#x2013;619. doi:&#xa0; 10.1152/physrev.00025.2019, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1152/physrev.00025.2019</ArticleId><ArticleId '
 'IdType="pmc">PMC7717128</ArticleId><ArticleId '
 'IdType="pubmed">32666886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen '
 'D, Xu Z, Xia L, Liu X, Tu Y, Lei H, et al. Important role of SUMOylation of '
 'Spliceosome factors in prostate cancer cells. J Proteome Res. (2014) '
 '13:3571&#x2013;82. doi:&#xa0; 10.1021/pr4012848, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1021/pr4012848</ArticleId><ArticleId '
 'IdType="pubmed">25027693</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang '
 'Y, Pan XW, Li L, Chen L, Liu X, Lu JL, et al. Overexpression of USP39 '
 'predicts poor prognosis and promotes tumorigenesis of prostate cancer via '
 'promoting EGFR mRNA maturation and transcription elongation. Oncotarget. '
 '(2016) 7:22016&#x2013;30. doi:&#xa0; 10.18632/oncotarget.7882, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.18632/oncotarget.7882</ArticleId><ArticleId '
 'IdType="pmc">PMC5008341</ArticleId><ArticleId '
 'IdType="pubmed">26959883</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan '
 'WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future '
 'perspectives. J Hematol Oncol. (2023) 16:57. doi:&#xa0; '
 '10.1186/s13045-023-01451-3, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s13045-023-01451-3</ArticleId><ArticleId '
 'IdType="pmc">PMC10225110</ArticleId><ArticleId '
 'IdType="pubmed">37245017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'X, Yu Q, Huang L, Yu P. Lentivirus-mediated inhibition of USP39 suppresses '
 'the growth of gastric cancer cells via PARP activation. Mol Med Rep. (2016) '
 '14:301&#x2013;6. doi:&#xa0; 10.3892/mmr.2016.5252, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/mmr.2016.5252</ArticleId><ArticleId '
 'IdType="pubmed">27175747</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong '
 'X, Su H, Jiang F, Li H, Shi G, Fan L. miR-133a, directly targeted USP39, '
 'suppresses cell proliferation and predicts prognosis of gastric cancer. '
 'Oncol Lett. (2018) 15:8311&#x2013;8. doi:&#xa0; 10.3892/ol.2018.8421, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3892/ol.2018.8421</ArticleId><ArticleId '
 'IdType="pmc">PMC5950022</ArticleId><ArticleId '
 'IdType="pubmed">29805563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'Y, Zhou D, Kong Y, Yang Q, Ding Y, Wang W. USPs in pancreatic ductal '
 'adenocarcinoma: A comprehensive bioinformatic analysis of expression, '
 'prognostic significance, and immune infiltration. BioMed Res Int. (2022) '
 '2022:6109052. doi:&#xa0; 10.1155/2022/6109052, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1155/2022/6109052</ArticleId><ArticleId '
 'IdType="pmc">PMC9794441</ArticleId><ArticleId '
 'IdType="pubmed">36582601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai '
 'J, Liu T, Huang P, Yan W, Guo C, Xiong L, et al. USP39, a direct target of '
 'microRNA-133a, promotes progression of pancreatic cancer via the AKT '
 'pathway. Biochem Biophys Res Commun. (2017) 486:184&#x2013;90. doi:&#xa0; '
 '10.1016/j.bbrc.2017.03.025, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.bbrc.2017.03.025</ArticleId><ArticleId '
 'IdType="pubmed">28286270</ArticleId></ArticleIdList></Reference><Reference><Citation>An '
 'L, Li M, Jia Q. Mechanisms of radiotherapy resistance and radiosensitization '
 'strategies for esophageal squamous cell carcinoma. Mol Cancer. (2023) '
 '22:140. doi:&#xa0; 10.1186/s12943-023-01839-2, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12943-023-01839-2</ArticleId><ArticleId '
 'IdType="pmc">PMC10439611</ArticleId><ArticleId '
 'IdType="pubmed">37598158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu '
 'X, Ma J, Lu M, Liu Z, Sun Y, Chen H. The deubiquitinase USP39 promotes '
 'esophageal squamous cell carcinoma Malignancy as a splicing factor. Genes '
 '(Basel). (2022) 13:819. doi:&#xa0; 10.3390/genes13050819, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3390/genes13050819</ArticleId><ArticleId '
 'IdType="pmc">PMC9141838</ArticleId><ArticleId '
 'IdType="pubmed">35627203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao '
 'Y, Geng H, Liu G, Ji Q, Cheng X, Li X, et al. The deubiquitinase USP39 '
 'promotes ESCC tumorigenesis through pre-mRNA splicing of the mTORC2 '
 'component rictor. Front Oncol. (2021) 11:667495. doi:&#xa0; '
 '10.3389/fonc.2021.667495, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3389/fonc.2021.667495</ArticleId><ArticleId '
 'IdType="pmc">PMC8189149</ArticleId><ArticleId '
 'IdType="pubmed">34123832</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu '
 'Y, Wang Y, Hu W, Hu C, Wang B, Liu C, et al. USP39 promotes the viability '
 'and migration of head and neck squamous cell carcinoma cell by regulating '
 'STAT1. Technol Cancer Res Treat. (2024) 23:15330338241250298. doi:&#xa0; '
 '10.1177/15330338241250298, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1177/15330338241250298</ArticleId><ArticleId '
 'IdType="pmc">PMC11072062</ArticleId><ArticleId '
 'IdType="pubmed">38706215</ArticleId></ArticleIdList></Reference><Reference><Citation>Li '
 'KY, Zhang J, Jiang LC, Zhang B, Xia CP, Xu K, et al. Knockdown of USP39 by '
 'lentivirus-mediated RNA interference suppresses the growth of oral squamous '
 'cell carcinoma. Cancer biomark. (2016) 16:137&#x2013;44. doi:&#xa0; '
 '10.3233/cbm-150549, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3233/cbm-150549</ArticleId><ArticleId '
 'IdType="pubmed">26835714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie '
 'T, Pi G, Yang B, Ren H, Yu J, Ren Q, et al. Long non-coding RNA 520 is a '
 'negative prognostic biomarker and exhibits pro-oncogenic function in '
 'nasopharyngeal carcinoma carcinogenesis through regulation of '
 'miR-26b-3p/USP39 axis. Gene. (2019) 707:44&#x2013;52. doi:&#xa0; '
 '10.1016/j.gene.2019.02.093, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.gene.2019.02.093</ArticleId><ArticleId '
 'IdType="pubmed">30898716</ArticleId></ArticleIdList></Reference><Reference><Citation>An '
 'Y, Yang S, Guo K, Ma B, Wang Y. Reduced USP39 expression inhibits Malignant '
 'proliferation of medullary thyroid carcinoma. vitro. World J Surg Oncol. '
 '(2015) 13:255. doi:&#xa0; 10.1186/s12957-015-0669-4, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12957-015-0669-4</ArticleId><ArticleId '
 'IdType="pmc">PMC4549085</ArticleId><ArticleId '
 'IdType="pubmed">26303214</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao '
 'Y, Zhang B, Lei Y, Sun J, Zhang Y, Yang S, et al. Knockdown of USP39 induces '
 'cell cycle arrest and apoptosis in melanoma. Tumour Biol. (2016) '
 '37:13167&#x2013;76. doi:&#xa0; 10.1007/s13277-016-5212-x, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1007/s13277-016-5212-x</ArticleId><ArticleId '
 'IdType="pubmed">27456357</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu '
 'C, Yao X, Li M, Xi Y, Zhao L. USP39 regulates the cell cycle, survival, and '
 'growth of human leukemia cells. Biosci Rep. (2019) 39:BSR20190040. '
 'doi:&#xa0; 10.1042/bsr20190040, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1042/bsr20190040</ArticleId><ArticleId '
 'IdType="pmc">PMC6449567</ArticleId><ArticleId '
 'IdType="pubmed">30898977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen '
 'YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. '
 'Lancet. (2019) 394:64&#x2013;80. doi:&#xa0; 10.1016/s0140-6736(19)30956-0, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/s0140-6736(19)30956-0</ArticleId><ArticleId '
 'IdType="pubmed">31178151</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage '
 'SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, et al. '
 'Genome-wide association study identifies two susceptibility loci for '
 'osteosarcoma. Nat Genet. (2013) 45:799&#x2013;803. doi:&#xa0; '
 '10.1038/ng.2645, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/ng.2645</ArticleId><ArticleId '
 'IdType="pmc">PMC3910497</ArticleId><ArticleId '
 'IdType="pubmed">23727862</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan '
 'Z, Han K, Lin S, Hu H, Shen Z, Min D. Knockdown of ubiquitin-specific '
 'peptidase 39 inhibited the growth of osteosarcoma cells and induced '
 'apoptosis. vitro. Biol Res. (2017) 50:15. doi:&#xa0; '
 '10.1186/s40659-017-0121-z, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s40659-017-0121-z</ArticleId><ArticleId '
 'IdType="pmc">PMC5389082</ArticleId><ArticleId '
 'IdType="pubmed">28403900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang '
 'J, Ma B, Li X, Jin W, Han C, Wang L, et al. MiR-1281, a p53-responsive '
 'microRNA, impairs the survival of human osteosarcoma cells upon ER stress '
 'via targeting USP39. Am J Cancer Res. (2018) 8:1764&#x2013;74., '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="pmc">PMC6176178</ArticleId><ArticleId '
 'IdType="pubmed">30323969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu '
 'J, Yuan S, Song J, Yu S. USP39 interacts with SIRT7 to promote cervical '
 'squamous cell carcinoma by modulating autophagy and oxidative stress via '
 'FOXM1. J Transl Med. (2023) 21:807. doi:&#xa0; 10.1186/s12967-023-04623-4, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1186/s12967-023-04623-4</ArticleId><ArticleId '
 'IdType="pmc">PMC10641974</ArticleId><ArticleId '
 'IdType="pubmed">37957720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei '
 'S, Zhang J, Zhao R, Shi R, An L, Yu Z, et al. Histone lactylation promotes '
 'Malignant progression by facilitating USP39 expression to target '
 'PI3K/AKT/HIF-1&#x3b1; signal pathway in endometrial carcinoma. Cell Death '
 'Discov. (2024) 10:121. doi:&#xa0; 10.1038/s41420-024-01898-4, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41420-024-01898-4</ArticleId><ArticleId '
 'IdType="pmc">PMC10923933</ArticleId><ArticleId '
 'IdType="pubmed">38459014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang '
 'Q, Sun Z, Xia W, Sun L, Du Y, Zhang Y, et al. Role of USP13 in physiology '
 'and diseases. Front Mol Biosci. (2022) 9:977122. doi:&#xa0; '
 '10.3389/fmolb.2022.977122, PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.3389/fmolb.2022.977122</ArticleId><ArticleId '
 'IdType="pmc">PMC9515447</ArticleId><ArticleId '
 'IdType="pubmed">36188217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding '
 'W, Wang JX, Wu JZ, Liu AC, Jiang LL, Zhang HC, et al. Targeting proteasomal '
 'deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil '
 'resistance in colorectal cancer cells. Acta Pharmacol Sin. (2023) '
 '44:2537&#x2013;48. doi:&#xa0; 10.1038/s41401-023-01136-0, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1038/s41401-023-01136-0</ArticleId><ArticleId '
 'IdType="pmc">PMC10692219</ArticleId><ArticleId '
 'IdType="pubmed">37528233</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan '
 'D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, et al. A small '
 'molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in '
 'multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. '
 '(2012) 22:345&#x2013;58. doi:&#xa0; 10.1016/j.ccr.2012.08.007, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.ccr.2012.08.007</ArticleId><ArticleId '
 'IdType="pmc">PMC3478134</ArticleId><ArticleId '
 'IdType="pubmed">22975377</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu '
 'J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of '
 'p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. '
 '(2011) 147:223&#x2013;34. doi:&#xa0; 10.1016/j.cell.2011.08.037, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.1016/j.cell.2011.08.037</ArticleId><ArticleId '
 'IdType="pmc">PMC3441147</ArticleId><ArticleId '
 'IdType="pubmed">21962518</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto-Garcia '
 'C, Hartmann O, Reissland M, Braun F, Fischer T, Walz S, et al. Maintaining '
 'protein stability of &#x394;Np63 via USP28 is required by squamous cancer '
 'cells. EMBO Mol Med. (2020) 12:e11101. doi:&#xa0; 10.15252/emmm.201911101, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.15252/emmm.201911101</ArticleId><ArticleId '
 'IdType="pmc">PMC7136964</ArticleId><ArticleId '
 'IdType="pubmed">32128997</ArticleId></ArticleIdList></Reference><Reference><Citation>Potu '
 'H, Peterson LF, Pal A, Verhaegen M, Cao J, Talpaz M, et al. Usp5 links '
 'suppression of p53 and FAS levels in melanoma to the BRAF pathway. '
 'Oncotarget. (2014) 5:5559&#x2013;69. doi:&#xa0; 10.18632/oncotarget.2140, '
 'PMID:</Citation><ArticleIdList><ArticleId '
 'IdType="doi">10.18632/oncotarget.2140</ArticleId><ArticleId '
 'IdType="pmc">PMC4170643</ArticleId><ArticleId '
 'IdType="pubmed">24980819</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation '
 'Status="PubMed-not-MEDLINE" Owner="NLM"><PMID '
 'Version="1">40909523</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article '
 'PubModel="Electronic"><Journal><ISSN '
 'IssnType="Electronic">2692-8205</ISSN><JournalIssue '
 'CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>bioRxiv '
 ': the preprint server for '
 'biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>MYC-Driven '
 'Activation of USP39 Enhances SRSF1 Stability and Promotes PDAC '
 'Progression.</ArticleTitle><ELocationID EIdType="pii" '
 'ValidYN="Y">2025.08.22.671882</ELocationID><ELocationID EIdType="doi" '
 'ValidYN="Y">10.1101/2025.08.22.671882</ELocationID><Abstract><AbstractText>Pancreatic '
 'ductal adenocarcinoma (PDAC) is a highly lethal malignancy primarily driven '
 'by oncogenic KRAS signaling. The splicing factor SRSF1 plays a key oncogenic '
 'role in PDAC, where its tightly regulated expression constrains KRAS-driven '
 'signaling under normal conditions, while its upregulation promotes '
 'tumorigenesis. SRSF1 expression is regulated in part by proteostasis. '
 'However, the precise mechanisms remain unclear. Here, we identify USP39 as a '
 'deubiquitinase that interacts with SRSF1 in an RNA-independent manner and '
 'stabilizes it by reducing ubiquitination. USP39 expression is elevated in '
 'PDAC tumors and precancerous lesions, and correlates with poor patient '
 'survival. <i>USP39</i> knockdown suppresses PDAC cell proliferation and '
 'migration, effects that are partially rescued by SRSF1 overexpression. '
 'Mechanistically, we show that MYC directly activates <i>USP39</i> '
 'transcription via E-box motifs within its exon 1b promoter, linking '
 'MYC-driven transcriptional regulation to post- translational stabilization '
 'of SRSF1. Together, these findings define a MYC-USP39-SRSF1 regulatory axis '
 'that integrates transcriptional and post-translational mechanisms in PDAC '
 'and highlight USP39 as a potential therapeutic '
 'target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author '
 'ValidYN="Y"><LastName>Ma</LastName><ForeName>Benteng</ForeName><Initials>B</Initials></Author><Author '
 'ValidYN="Y"><LastName>Kral</LastName><ForeName>Alexander '
 'J</ForeName><Initials>AJ</Initials></Author><Author '
 'ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author '
 'ValidYN="Y"><LastName>Singh</LastName><ForeName>Neelu</ForeName><Initials>N</Initials></Author><Author '
 'ValidYN="Y"><LastName>Deschenes</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author '
 'ValidYN="Y"><LastName>Cifani</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author '
 'ValidYN="Y"><LastName>Park</LastName><ForeName>Youngkyu</ForeName><Initials>Y</Initials></Author><Author '
 'ValidYN="Y"><LastName>Tuveson</LastName><ForeName>David '
 'A</ForeName><Initials>DA</Initials></Author><Author '
 'ValidYN="Y"><LastName>Krainer</LastName><ForeName>Adrian '
 'R</ForeName><Initials>AR</Initials></Author><Author '
 'ValidYN="Y"><LastName>Wan</LastName><ForeName>Ledong</ForeName><Initials>L</Initials><Identifier '
 'Source="ORCID">0000-0002-2450-3986</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType '
 'UI="D016428">Journal Article</PublicationType><PublicationType '
 'UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate '
 'DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United '
 'States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate '
 'PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>5</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate '
 'PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId '
 'IdType="pubmed">40909523</ArticleId><ArticleId '
 'IdType="pmc">PMC12407777</ArticleId><ArticleId '
 'IdType="doi">10.1101/2025.08.22.671882</ArticleId><ArticleId '
 'IdType="pii">2025.08.22.671882</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>')